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Despite recent advances in its management, heart failure remains a major cause 
of disability and death and its prevalence is still increasing as the population ages. 
However, rapid and accurate bedside diagnosis, evaluation as well as risk 
stratification of heart failure still remain challenging.  
 
Acoustic cardiography (AUDICOR, Inovise Medical, Inc., Portland, OR, USA) 
is a novel and user friendly equipment which can be used in a wide variety of clinical 
conditions. With proprietary dual-functional sensors, this technology permits 
simultaneous acquisition of detailed information regarding systolic time intervals and 
diastolic heart sounds and provides a computerized interpretation of the findings. 
Major acoustic cardiographic parameters include S3 score (probability that the third 
heart sound exists), electromechanical activation time (EMAT, interval from Q wave 
to the first heart sound; %EMAT is the proportion of cardiac cycle that EMAT 
occupies), and systolic dysfunction index (SDI= exp [S3 score/10] x QRS interval x 
QR interval x %EMAT).This thesis will cover 3 aspects of clinical application of 
acoustic cardiography in heart failure patients. 
 
I. Identification of heart failure and its phenotypes 
We performed one study involving 94 patients with hypertension without heart 
failure, 109 patients with heart failure with normal ejection fraction (HFNEF, EF > 
50%) and 89 patients with heart failure and reduced ejection fraction (HFREF, EF < 
50%). We found that %EMAT significantly differentiated HFNEF from hypertension. 
Whereas SDI out-performed the other acoustic cardiographic parameters in 
differentiating HFREF from HFNEF. 
 xix 
II. Assessment of HFREF patients at high risk by evaluating the severity of 
left ventricular (LV) systolic and diastolic dysfunction 
Ninety-four hypertensive patients without heart failure and 127 HFREF patients 
(EF < 50%) were consecutively recruited for the study. SDI significantly 
differentiated HFREF from hypertension. In subgroup analysis, SDI discriminated 
HFREF patients with severely impaired EF (EF ≤ 35%) from those with moderately 
impaired EF (35% < EF <50%). S3 score > 4.67 identified HFREF patients with 
restrictive LV filling pattern. 
 
III. Risk stratification in patients with heart failure 
A total of 474 patients hospitalized for heart failure were enrolled into our study. 
During a mean follow-up time of 484±316 days, 169 (35.7%) patients died and 125 
(26.4%) of them died of cardiac causes. After controlling for other potential 
confounders, we found that S3 score ≥ 4.12, and SDI ≥ 5 were both independent 
predictors for all-cause mortality. Kaplan-Meier analysis showed that heart failure 
patients with SDI ≥ 5 or S3 score ≥ 4.12 had a significantly lower survival rate than 
those with lower SDI or S3 score. 
 
In summary, this bedside technology offers a wide variety of clinical 
applications in (1) identification of heart failure and its phenotypes; (2) assessment of 
HFREF patients at high risk by evaluating the severity of LV systolic and diastolic 
dysfunction; (3) risk stratification in patients with heart failure. Thus, acoustic 
cardiography is likely to be helpful in the management of heart failure patients, 









（diastolic heart sounds）。這項技術提供的主要參數包括：第三心音分數（S3 
score；第三心音存在的可能性），電機械時間（EMAT, electromechanical activation 
time；從心電圖 Q 波到心音圖第一心音的時間）及電機械時間比例（%EMAT；
電機械時間占整個心動週期的比例），收縮障礙指數（SDI, systolic dysfunction 
index）。本論文主要涵蓋 Acoustic cardiography 在心力衰竭患者中如下三個方面
的應用： 
一、心力衰竭的診斷和不同亞型的識別 
本研究入組了 94 名高血壓但無心力衰竭患者、109 名射血分數正常的心力




此研究共招募 94 名高血壓患者和 127 名射血分數減低的心力衰竭患者。結
果顯示：SDI 可以鑒別射血分數減低的心力衰竭和高血壓患者。亞組分析顯示：




共計 474 名心力衰竭患者被納入此研究，平均隨訪時間 484±316 天，169
名患者死亡，其中 125 名死於心臟病。SDI 和 S3 score 都是全因死亡率的獨立


















PART I LITERATURE REVIEW 
 
 2 
Chapter 1 Introduction to Acoustic Cardiography 
1.1 History of auscultation, phonocardiography  
Since the invention of the stethoscope by Rene Laennec in 1816, auscultation has 
been an important tool to evaluate patients with known or suspected heart diseases.  
In particular, the auscultated third heart sound (S3) are considered as an important 
clinical marker of heart failure and its diagnostic and prognostic values were 
validated by many previous studies (Sloan, 1958; Shah et al., 1968; Ozawa et al., 
1983; Reddy, 1985; Glower et al., 1992; Kono et al., 1993; Drazner et al., 2001; 
Tribouilloy et al., 2001; Drazner et al., 2003; Rame et al., 2003). However, the poor 
inter-observer agreement regarding auscultation among physicians limits its clinical 
application (Ishmail et al., 1987; Lok et al., 1998). Further, with the advent of 
complex diagnostic modalities, auscultation skills deteriorated significantly over time 
(Mangione and Nieman, 1997; Jauhar, 2006). 
 
Phonocardiography was developed to facilitate the evaluation of heart sounds and 
murmurs. This technique permitted an analogue analysis of the timing and acoustical 
characteristics of the heart sounds and murmurs (Leatham, 1987). Later, through the 
work of Aubrey Leatham and William Evans in the late 1940s (creating a novel 
phonocardiography with the additional capability of recording simultaneous carotid 
pulse tracings and ECG data) and Weissler in 1960s (finding out the correlation of 
abnormal systolic time intervals [STIs] with left ventricular [LV] dysfunction), both 




1.2.1 Conventional STIs  
Combined with ECG, phonocardiography and the carotid pulse tracing, STIs could be 
provided which were one kind of the first quantitative measurements of cardiac 
function (Lewis et al., 1977). The three basic STIs were the pre-ejection period (PEP), 
the LV ejection time (LVET), and total electro-mechanical systolic time (QS2) as 
well as one derived parameter — PEP/LVET (figure 1.1).  
 
1. Total electro-mechanical systolic time (Q-S2 interval) 
The interval from the onset of the QRS to the aortic component of the second heart 
sound. 
2. Left ventricular ejection time (LVET) 
The interval from the beginning of the carotid upstroke to the dicrotic notch. 
3. Pre-ejection period (PEP) 
Because there is a transmission delay in the carotid pulse tracing, the PEP must be 




Figure 1. 1 Schematic of the LV events which comprise the STIs (Left) and 
recordings of a phonocardiogram, external carotid pulse, and electrocardiogram at 
100 mm/sec paper speed (Right) [from Lewis et al(Lewis et al., 1977)]. 
Abbreviations: Phono = phonocardiography; LV = left ventricular; LVET = left 




Prior studies proved that STIs correlated closely with LV function, such as 
angiographic LV end diastolic volume (LVEDV) (Garrard et al., 1970), LVEF 
(Garrard et al., 1970), and cardiac output with indicator-dilution technique (Weissler 
et al., 1968). Thus, these measurements should have a potential utility in diagnosis of 
heart failure as a non-invasive method. Whereas the complicated measurement of 
STIs that involved ECG, phonocardiography and carotid pulse tracing made a rapid 
diagnosis impossible (Lewis et al., 1977).  
 
1.1.2 Echocardiographic STI 
Tei and his colleagues introduced one derived index using conventional pulsed 
Doppler echocardiography (Figure 1.2), which is similar to the conventional STI 
parameters (Tei et al., 1995). This index is simple, non-invasive, easy to estimate and 
reproducible (Tei, 1995; Tei et al., 1996). Furthermore, a number of studies have 
documented that this index (namely Tei index) is correlated closely with the widely 
accepted systolic and diastolic hemodynamic parameters and is potentially useful in 
the assessment of overall cardiac performance (Tei et al., 1996; LaCorte et al., 2003). 
Tei index has also been shown to provide prognostic information in severe diseases, 
such as dilated cardiomyopathy (Dujardin et al., 1998; Ikeda et al., 2001), cardiac 





Figure 1. 2 Illustration of measurement of Tei index using Doppler echocardiography. 
The index is derived from the equation (a−b)/b, where a represents the interval 
between cessation and onset of the mitral inflow and b represents the ejection time of 
the left ventricular outflow. [from Karatzis et al (Karatzis et al., 2009)] 
Abbreviations: ICT = isovolumic contraction time; IRT = isovolumic relaxation time; 
ET = ejection time. 
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1.3 Acoustic cardiography 
Despite the early demonstration that STIs could be useful indicators of cardiac 
function, their application in clinical practice diminished. This phenomenon was 
partly due to the inherent difficulties of measuring traditional STIs and partly due to 
the increasing popularity of echocardiography and other modalities. 
 
Acoustic cardiography (Audicor®, Inovise Medical, Inc., Portland, OR, USA) is an 
inexpensive and easy to use equipment which can be used in a wide variety of 
clinical conditions (Erne, 2008) (Figure 1.3). With proprietary dual-functional 
sensors (Figure 1.4 and Figure 1.5), this technology permits simultaneous acquisition 
of detailed information regarding STIs and diastolic heart sounds and provides a 
computerized interpretation of the findings. 
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Figure 1. 4 Proprietary disposable dual-functional sensors of acoustic cardiography 
(Courtesy of Inovise Medical, Inc.) 
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Figure 1. 5 Proprietary reusable dual-functional sensors of acoustic cardiography (Courtesy of Inovise Medical, Inc.) 
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Acoustic cardiography with 12-lead or 4 lead can provide the basic measurements of 
ECG and STIs including the following parameters (Figure 1.7): 
 
1.3.1 ECG parameters of acoustic cardiography 
1. PR interval 
The PR interval is measured from the beginning of the P wave to the beginning of the 
QRS complex. The PR interval is a good marker for AV node function. It is usually 
120 to 200 ms long. An abnormal PR interval is associated with different types of 
heart block, pre-excitation syndrome or pericarditis.  
2. QR interval 
The QR interval is also known as intrinsicoid deflection or the R wave peak time. It 
is measured from the beginning of the QRS complex to the peak of the R wave. It is 
usually < 50ms. It reflects the depolarization vector from the endocardium to the 
epicardium. The prolonged QR interval is often associated with bundle branch block 
or ventricular hypertrophy. 
3. QRS duration/interval 
The QRS duration or QRS interval is measured from the QRS complex onset to its 
offset. The QRS duration is normally 80 to 120 ms long. It corresponds to the 
depolarization of the right and left ventricles. The abnormal QRS duration is useful 
in diagnosis of cardiac arrhythmias, conduction abnormalities, ventricular 
hypertrophy, and other disease states. 
4. QT interval 
The QT interval is measured from the start of the Q wave to the end of the T wave. In 
general, the QT interval represents electrical depolarization and repolarization of the 
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left and right ventricles. A lengthened QT interval is a marker for ventricular 
tachyarrhythmias like torsades de pointes and a risk factor for sudden death. 
5. QTc interval 
The QTc interval is equal to QT interval divided by the square root of the R to R 
interval (Bazett’s formula). This heart rate corrected variable is also used as a marker 
for increased risk for cardiac arrhythmias. 
 
1.3.2 Systolic parameters of acoustic cardiography 
1. Electro-Mechanical Activation Time (EMAT) 
EMAT is measured from the onset of QRS complex to the peak component of the 
first heart sound (S1). EMAT reflects the time required for LV to generate sufficient 
force to close the mitral valve. Thus, EMAT indicates the rate of LV pressure 
development and is similar to LV max (dp/dt). The prolonged EMAT indicates lower 
dp/dt or longer electro-mechanical delay and is specific for impaired systolic 
function. 
2. %EMAT 
%EMAT indicates the proportion of the cardiac cycle that EMAT occupies. 
3. LV Systolic Time (LVST) 
LVST is the interval measured from S1 to the second heart sound (S2). It is 
influenced by systolic function, contractility and preload/afterload.  
4. %LVST 
%LVST indicates the proportion of the cardiac cycle that LVST occupies. 
5. Systolic Dysfunction Index (SDI) 
SDI= exp (S3 score/10) x QRS duration x QR interval x %EMAT. The SDI value 
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undergoes a nonlinear transformation and is mapped into a scale of 0 – 10, where 
SDI > 5 indicates EF < 50% and SDI > 7.5 indicates EF < 35% and elevated LV 
filling pressure. This parameter was developed on separate learn and test sets of 
invasive cardiac catheterization data that provided both EF and LV end-diastolic 
pressure. 
 
1.3.3 Diastolic Parameters of acoustic cardiography 
1. LV Diastolic Perfusion Time (LDPT)  
LDPT is the interval from S2 to the next Q wave onset.  
2. LV Diastolic Time (LVDT)  
LVDT is the interval from S2 to the next S1. 
3. Pre-Atrial Filling Time (PAFT) 
PAFT is the interval from S2 to the next P wave onset. 
4. Atrial Accelerated Filling Time (AAFT) 
AAFT is the interval from P wave onset to S1. 
5. S3 score/S3 strength 
It is the probability that S3 exists. On the basis of timing, persistency, intensity, 
frequency of the sound, one value between 0 and 10 is reported. Values > 5 indicate 
S3 is present. 
6. S4 score/S4 strength 
It is the probability that S4 exists. On the basis of timing, persistency, intensity, 
frequency of the sound, one value between 0 and 10 is reported. Values > 5 indicate 
S4 is present. 
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Figure 1.8 and Figure 1.9 show acoustic cardiographic sample reports with a 12-lead 




Figure 1. 6 The diagram of main acoustic cardiographic parameters (Courtesy of 
Inovise Medical, Inc.).  
Abbreviations: ECG = electrocardiogram; S1 = the first heart sound; S2 = the second 
heart sound; S3 = the third heart sound; S4 = the fourth heart sound; EMAT = 
electromechanical activation time; LVST = left ventricular systolic time; LVDT = left 
ventricular diastolic time; LDPT = left ventricular diastolic perfusion time; PAFT : 
pre-atrial filling time; Ao = aortic; LA= left atrium; LV = left ventricular. 
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Figure 1. 7 A sample of acoustic cardiographic report with 12-lead ECG (Courtesy of Inovise Medical, Inc.). 
 17 
Besides standard 12-lead ECG, a simultaneous sound tracing that reveals both S3 and the fourth heart sound (S4) was provided in this 
report. A segment of this sound tracing is also shown near the top right corner of the report and all kinds of heart sounds were labeled. 
The ECG findings included an anterior myocardial infarction and evidence of left ventricular hypertrophy. The three dimensional image 
of the heart in the top right corner indicated the location of myocardial infarction in black ink. Below the image of the three dimensional 
image of the heart is a horizontal bar graph that indicated the relative strength of the ECG evidence for the left ventricular hypertrophy. 
Abbreviations: int = interval; dur = duration; LVH = left ventricular hypertrophy; mV = millivolt; S1 = the first heart sound; S2 = the 
second heart sound; S3 = the third heart sound; S4 = the fourth heart sound; EMAT = electromechanical activation time; LVST = left 




Figure 1. 8 A sample of acoustic cardiographic report with 4-lead ECG (Courtesy of Inovise Medical, Inc.). Only one lead ECG and 
sound tracing was provided. Abbreviations: int = interval; S1 = the first heart sound; S2 = the second heart sound; S3 = the third heart 
sound; EMAT = electromechanical activation time; LVST = left ventricular systolic time. 
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1.4 Comparison between acoustic cardiography and traditional 
phonocardiography 
Both acoustic cardiography and traditional phonocardiography can provide visual 
recording of heart sounds. However, traditional phonocardiography is similar to 
auscultation because both of them can only provide qualitative information about the 
target sounds, ie present or absent. In contrast, with sophisticated wavelet-based 
signal processing techniques which are much more reliable than the auscultation and 
traditional phonocardiography, acoustic cardiography evaluates the heart sound data 
quantitatively based on an algorithm using large, independently validated clinical 
database. The raw sound data undergoes a time-frequency analysis (Figure 1.10 and 
Figure 1.11), which enables to discriminate heart sounds from murmurs and artifacts 
(Figure 1.12, Figure 1.13), even applicable and accurate in morbid obesity (Figure 
1.14). Additionally, the mitral, tricuspid, aortic and pulmonary valve closure have a 
very specific time-frequency “fingerprint”, which permits the separation of different 
components of S1 and S2. 
 
Acoustic cardiography also simplifies the old process of STIs measurement by 
eliminating the carotid pulse tracing. It can be performed by a technician without 
additional special training who is able to perform a traditional ECG, by replacing the 
V3 and V4 leads with the proprietary dual functional sensors. Results are 
automatically calculated and immediately available. 
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Figure 1. 9 Illustration of time-frequency analysis of heart sounds (Courtesy of 
Inovise Medical, Inc.). 
Abbreviations: ECG = electrocardiogram; Phono = phonocardiography; S1 = the first 






Figure 1. 10 Acoustic cardiographic report and time-frequency analysis of one 
subject with S3 (Courtesy of Inovise Medical, Inc.).  
The upper panel is the acoustic cardiographic report; middle and below panels are 2D 
and 3D scalograms for heart sounds within 2 beats. S3 can be easily identified in 3D 
scalogram for analysis. 
Abbreviations: S1 = the first heart sound; S2 = the second heart sound; S3 = the third 





Figure 1. 11 Acoustic cardiographic report and time-frequency analysis of one 
subject with S3, S4 and systolic murmurs (Courtesy of Inovise Medical, Inc.).  
The upper panel is the acoustic cardiographic report; middle and below panels are 2D 
and 3D scalograms for heart sounds within 3 beats. 





Figure 1. 12 Acoustic cardiographic report and time-frequency analysis of one 
subject with episodes of snoring (Courtesy of Inovise Medical, Inc.).  
The upper panel is the acoustic cardiographic report; middle and below panels are 2D 
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and 3D scalograms for heart sounds within 2 beats. Due to the different frequency of 
pulmonary noises, it is easy for the algorithm to discriminate them from hearts 






Figure 1. 13 Acoustic cardiographic report and time-frequency analysis of one 
subject with high body mass – 560 pounds (Courtesy of Inovise Medical, Inc.).  
The upper panel is the acoustic cardiographic report; middle and below panels are 2D 
and 3D scalograms for heart sounds within 3 beats. Although the amplitude of heart 
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sounds in this subject is dramatically lower than in the normal weighted subjects, the 
“fingerprint” for each sound is as clear as in normal weighted subjects. Thus, 
accurate analysis of heart sounds can be obtained. 




Chapter 2 Clinical Application of Acoustic Cardiography 
It can be appreciated from the previous chapter that acoustic cardiography offers the 
possibility of a rapid and non-invasive cardiac assessment which can be used to 
evaluate patients with known or suspected heart diseases. There are a wide variety of 
both investigational and clinical applications of this technology. 
 
2.1 Mechanism of generation of S3 and S4 
S3 is a low-frequency, brief vibration occurring in early diastole at the end of the 
rapid diastolic filling period. Synonymous terms include: ventricular gallop, early 
diastolic gallop, ventricular filling sound. And the best description was provided by 
Pierre Carl Potain. Extensive studies including animal models and human studies 
have demonstrated that the S3 reflects elevated ventricular diastolic filling pressure 
(Shah et al., 1968), rapid early diastolic filling (Glower et al., 1992; Tribouilloy et al., 
2001), increased ventricular stiffness (Kono et al., 1993), volume overload, and an 
abrupt deceleration of early diastolic filling (Ozawa et al., 1983). 
 
Of the many proposed theories, the most likely explanation for the generation of S4 
is that when the atrial contraction rapidly distends the ventricle, the stiff, 
noncompliant ventricular wall reaches its physical limits, it suddenly tenses, and S4 
is generated. Thus, S4 is known as the atrial gallop.  
 
However, all of these studies were performed with auscultation or conventional 
phonocardiography; they could not evaluate the heart sounds information 
quantitatively. Several studies using acoustic cardiography were designed to reveal 
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the potential mechanism. 
 
Shah SJ et al. (Shah et al., 2008) studied the physiology of S3 in 90 patients using 
acoustic cardiography, catheterization and tissue Doppler imaging. They found that 
subjects with an S3 had lower ejection fraction (p < 0.0006) and increased E 
deceleration rate (p < 0.0001), E/e′ (p < 0.0001) and filling pressures (p < 0.0001). 
S3 correlated with E/e′(r = 0.46; p < 0.0001) and E deceleration rate (r = 0.43, p = 
0.0001). Of the echocardiographic variables, only E/e′ was independently associated 
with the S3 score (p = 0.009), independently of invasively determined LV filling 
pressures (p = 0.001).  
 
The same group (Shah et al., 2008) also investigated the relationship between S4 and 
the end-diastolic pressure volume relationship (EDPVR) in 90 participants 
undergoing acoustic cardiographic analysis, echocardiography, and left heart 
catheterization. In the P = alphaV(beta) EDPVR estimation, alpha was similar (p = 
0.31), but beta was significantly higher in the S4 group (5.96 versus 6.51, p = 0.002), 
signifying a steeper, upward- and leftward-shifted EDPVR curve in subjects with an 
S4. S4 was associated with both beta (r = 0.42, p < 0.0001) and E/e′ / stroke volume 
index, another index of diastolic stiffness (r = 0.39, p = 0.0008). In multivariable 
analysis, beta remained associated with the presence (p = 0.008) and intensity (p < 
0.0001) of S4 after controlling for age, sex, and ejection fraction. 
 
2.2 Prevalence of S3 and S4 
The prevalence of diastolic heart sounds has been a subject of great debate due to the 
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poor agreement in auscultation. Several studies have been conducted to evaluate the 
prevalence of diastolic heart sounds in different cohorts. 
 
Collins SP et al. (Collins et al., 2005) conducted a large epidemiologic study to 
determine the prevalence of S3 and S4 in asymptomatic adults. The overall 
prevalence of S3 was 10.0% (95% CI, 8.1%–12.2%), S4 was 15.6% (95% CI, 
13.2%–18.2%), and both S3 and S4 were 3.5% (95% CI, 2.4%–5.0%). Using 
multinomial logistic regression, increasing age was found to decrease the odds of an 
S3 being heard (odds ratio, 0.96; 95% CI, 0.95–0.96) and increase the odds of an S4 
being heard (odds ratio, 1.04; 95% CI, 1.03–1.05).  
 
Collins SP et al. (Collins et al., 2006) also studied 376 patients with suspected heart 
failure. They found of 59 patients with heart failure before treatment, 57.6% had S3 
and 35.6% had S4. For the 35 patients with heart failure evaluated after treatment, 
the proportions of both S3 and S4 were lower (28.6% and 8.6%, respectively; p ≤ 
0.0064). 
 
Dillier R et al. (Dillier et al., 2011) studied 128 symptomatic subjects. In these 
asymptomatic subjects, S3 was significantly more prevalent in those age <40 years 
than in those age >40 years, and significantly more pronounced during sleep in the 
younger group. Also, S4 was significantly more prevalent in those age >40 years and 
significantly more pronounced during sleep in those age >40 years. 
 
2.3 Clinical auscultation of S3 and S4 problems 
The diastolic heart sounds are considered as important clinical marker for LV 
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dysfunction. S3 portends increased risk in patients undergoing non-cardiac surgeries 
(Goldman et al., 1977), and is associated with adverse outcome with in patients with 
heart failure (Drazner et al., 2001) and acute myocardial infarction (Maisel et al., 
1985). S4 is generally considered as abnormal and may be evident in patient with 
hypertension, acute myocardial infarction, or heart failure. The presence of S4 is 
associated with adverse outcomes in patients with acute myocardial infarction 
(Ishikawa et al., 1997).  
 
However, S3 is often the most difficult heart sound to hear because the sound is 
usually of very low intensity and is easily obscured by other noises; the sound does 
not radiate widely and is only audible in a small area of chest wall; the usual 
frequency is near the lowest level that human ears can detect. S4 occurs just after 
atrial contraction and immediately before S1. It is very difficult to differentiate a spilt 
S1 from an S4-S1. Since the auscultation of diastolic heart sounds are very important 
but challenging, there is a clinical need for a bedside diagnostic tool to improve it.  
 
Marcus G et al. (Marcus et al., 2006) and Gupta S et al. (Gupta and Michaels, 2009) 
performed studies to examine agreement in auscultation of S3 and S4 across different 
levels of auscultation using objective correlate of the sound itself and objective 
diagnostic testing of cardiac function. One hundred patients undergoing 
non-emergent LV catheterization and 26 cardiology attendings, 18 cardiology 
fellows, 54 internal medicine residents and 48 internal medicine interns representing 
different levels of experience in auscultation participated in this study. The authors 
found that resident's and intern's auscultatory findings demonstrated no significant 
agreement with acoustic cardiographic findings, whereas S3 auscultated by 
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cardiology fellows (κ = 0.37; p < 0.001) and cardiology attendings (κ = 0.37; p < 
0.001) agreed with acoustic cardiographic findings. Only S4 auscultated by 
cardiology attendings had moderate diagnostic accuracy with acoustic cardiography 
(odds ratio: 2.31; AUC: 0.60).  
 
In diagnostic test, S3 identified abnormal LV function with low sensitivities 
(13%–51%) and high specificities (85%–95%) with the best test characteristics 
exhibited by acoustic cardiography and more experienced physicians. The 
sensitivities of the S4 were low (39%–46%) for identifying patients with abnormal 
measures of LV filling pressure (B-type natriuretic peptide [BNP] and LVEDP, 
respectively), and the specificities were fair (76%–80%). Overall the auscultation of 
S3 and S4 improved with advancing levels of experience. Acoustic cardiography 
provided the best performance in detecting abnormal LV function. 
 
Michaels AD et al. (Michaels et al., 2010) performed one study to investigate 
whether visual inspection of acoustic cardiographic tracings augmented the accuracy 
of medical students' and physicians' detection of S3 and S4 compared to auscultation 
alone. With the assistance of acoustic cardiography, first-year medical students had 
minimal improvement in S3 (2%) and S4 (11%) accuracy. More experienced 
subjects improved S3 accuracy by 8% to 18% and S4 by 15% to 32% (p < 0.05).  
 
McCullough PA et al. (McCullough et al., 2010) reported one study involving 190 
individuals with morbid obesity examined by acoustic cardiography and senior 
attending physicians. The overall body mass index was 47.3±12.3 kg/m2. Of those 
with detected S3 (n = 7) by acoustic cardiography, one had a history of coronary 
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artery disease, none had a history of heart failure, and one had a LVEF < 45%. By 
contrast, of those (n = 6) with S3 detected by conventional stethoscope, one had a 
history of CAD, two had histories of heart failure, and 3 had LVEF < 45%. There 
were 40 (21.1%) patients with S4 detected by acoustic cardiography and 42 (22.1%) 
patients with S4 identified by the stethoscope and 9 patients with S4 detected by both 
acoustic cardiography and stethoscope (21.4% concordance). The authors concluded 
that the careful clinical exam with attention to traditional auscultation using a 
stethoscope in a quiet room should remain the gold standard. 
 
2.4 Rapid identification of heart failure or LV dysfunction 
Because many of the signs and symptoms of heart failure are nonspecific (e.g., 
dyspnea), accurate and rapid diagnosis of heart failure is challenging. Previous 
studies suggest the emergency department misdiagnosis rate of heart failure is 
10-20%. A serial of studies regarding diagnostic characteristics of acoustic 
cardiography were published in the past few years. 
 
2.4.1 S3 and S4 
In a multinational study (HEARD-IT) (Collins et al., 2009) enrolling 995 dyspneic 
patients admitted in emergency department, acoustic cardiography had an accuracy 
of 68% (95% CI, 65.4%–71.3%), a sensitivity of 40.2% (95% CI, 35.5%–45.1%), 
and a specificity of 88.5% (95% CI, 85.5%–90.9%) in diagnosis of acute 
decompensated heart failure. Emergency physician confidence and diagnostic 
accuracy were influenced by adding information about the presence or absence of S3.  
 
 33 
Collins SP et al. (Collins et al., 2006) investigated 343 emergency department 
patients with undifferentiated dyspnea, they found the sensitivity, specificity, positive 
and negative predictive value, and diagnostic accuracy of an electronic S3 for 
primary heart failure were 34% (95% CI, 26%–43%), 93% (95% CI, 89%–96%), 
66% (95% CI, 57%–74%), 7% (95% CI, 4%–11%), and 70% (95% CI, 65%–75%) 
and for physician auscultation were 16% (95% CI, 11%–24%), 97% (95% CI, 
93%–99%), 84% (95% CI, 76%–89%), 3% (95% CI, 2%–7%), and 66% (95% CI, 
61%–71%). 
 
In another study involving 90 adult patients undergoing elective left-sided heart 
catheterization (Marcus et al., 2005), the authors reported the sensitivities of S3 and 
S4 to detect an elevated LVEDP, reduced LVEF, or elevated BNP were 41%, 52%, 
and 32% for an S3, and 46%, 43%, and 40% for an S4, respectively. For abnormal 
levels of the same markers of ventricular function, the specificities of the S3 were 




In one study of 100 adult patients undergoing left heart catheterization, Moyers B et 
al. (Moyers et al., 2007) found EMAT ≥ 15 had 44% sensitivity, 94% specificity, and 
7.0 likelihood ratio for left ventricular dysfunction, while EMAT/LVST ≥ 0.4 had 
55% sensitivity, 95% specificity, and 11.7 likelihood ratio. 
 
In another study involving 108 patients who underwent elective diagnostic cardiac 
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catheterization, Roos M et al. (Roos et al., 2008) defined left ventricular systolic 
dysfunction (LVSD) as a maximum LV maximal dP/dt <1600 mm Hg/s and found at 
thresholds of 100 and 110 ms, EMAT had sensitivities of 53% and 42%, and 
specificities of 90% and 100% in detecting LVSD, respectively. EMAT performed 
better than LVEF or QRS duration in hemodynamic subgroups. 
 
2.4.3 SDI 
Dillier R et al. (Dillier et al., 2010) tested the diagnostic ability of acoustic 
cardiography in patients with atrial fibrillation. LVSD was defined as LV maximum 
dP/dt <1600 mmHg/s. Acoustic cardiography detected systolic dysfunction with high 
specificity and moderate sensitivity with similar performance to EF 
(sensitivity/specificity without atrial fibrillation: EMAT 30/96, SDI 40/90, EF at 35% 
30/96; sensitivity/specificity with atrial fibrillation: EMAT 64/82, SDI 59/100, EF at 
35% 45/82). 
 
2.4.5 Other derived acoustic cardiographic parameters 
Zuber M et al. (Zuber et al., 2007) compared the diagnostic ability of QRS and one 
derived score from 4 acoustic cardiographic variables including QR interval, QRS 
interval, S3 score and %EMAT in 171 patients with possible chronic compensated or 
mildly decompensated heart failure as the learning population as well as 399 patients 
with signs or symptoms of decompensated heart failure as the test population. In the 
learning population, the sensitivities/specificities of QRS duration ≥ 120 ms and the 
score for prediction of LVSD (defined as LVEF < 50%) were 51%/92% and 
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77%/90%, respectively. In the test population, the score remained superior to QRS 
duration for detecting LVSD as well as acute decompensated heart failure. 
 
Shapiro M et al. (Shapiro et al., 2007) created the LV dysfunction index summarizing 
the Z score of acoustic cardiographic S3 and EMAT/LVST and test its diagnostic 
ability in 81 adult patients undergoing left heart catheterization. The LV dysfunction 
index had a correlation coefficient of 0.38 for LVEDP (p = 0.0003), -0.53 for LVEF 
(p < 0.0001), and 0.35 for BNP (p = 0.0008). This index had a receiver operating 
curve (ROC) c-statistic of 0.89 in diagnosing LV dysfunction (LV dysfunction was 
defined as both an LVEDP > 15 mm Hg and LVEF < 50%) with a cutoff > 1.87 
yielded 72% sensitivity, 92% specificity, 9.0 positive likelihood ratio (PLR), and 
88% accuracy. 
 
2.5 Predicting elevated LV filling pressure  
Patients presenting with acute dyspnea are often a diagnostic dilemma. A bedside 
tool that accurately and rapidly identifies increased LV filling pressure would be 
helpful. 
 
Collins SP et al. (Collins et al., 2009) developed one multivariable model including 
LVST, S3 score, maximum negative area of the P wave, and the QTc interval to 
predict elevated filling pressure defined as a pseudonormal or restrictive filling 
pattern on echocardiography. They tested this model in a cohort of 324 patients 
consisting of 124 patients with NSTEMI or acute decompensated heart failure and 91 
patients referring to non-emergency catheterization and 175 ambulatory patients. The 
area under ROC (AUC) of this model was 0.83 (95% CI, 0.78–0.88). The authors 
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(Collins et al., 2010) also validated this model in 68 adults referred for right heart 
catheterization. Elevated LV filling pressure was defined as a pulmonary capillary 
wedge pressure (PCWP) ≥ 15 mmHg. The AUC of this model is 0.72 (95% CI, 
0.60–0.85). When the regression model's parameters were held constant but the 
parameter estimates were allowed to vary, the AUC in the validated model was 0.76 
(95% CI, 0.64–0.88). At a specificity of 90% the PLR was 5.0 (1.7–15.3) and the 
negative likelihood ratio (NLR) was 0.49 (0.34–0.71). 
 
2.6 Improving diagnostic utility of BNP in detection of heart failure or LV 
dysfunction  
BNP is often used to evaluate patients with possible heart failure, but its frequently 
encountered intermediate “gray zone” between 100-500 pg/ml limited its diagnostic 
utility (Maisel et al., 2002). An additional test to resolve this problem would be 
desirable. Several previous studies were designed to test whether acoustic 
cardiography can improve the detection of heart failure or LV dysfunction in patients 
with non-diagnostic values of BNP. 
 
In a study of 164 outpatients referred for echocardiographic evaluation for suspected 
heart failure, 69 of 164 patients (42%) had BNP values in the "gray zone" of 100 to 
500 pg/ml. Zuber M et al. (Zuber et al., 2007) found sensitivity and specificity for LV 
dysfunction of BNP in the gray zone were 55% and 75%, with a PLR of 2.3. The use 
of acoustic cardiographic parameters in these 69 patients increased sensitivity and 
specificity to 69% and 100%, with a corresponding PLR of 69. 
 
In one study of 100 adult patients undergoing left heart catheterization, Moyers B et 
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al. (Moyers et al., 2007) found in patients with an intermediate BNP (100-500 
pg/mL), the PLR increased from 1.1 using the BNP result alone to 11.0 when adding 
a positive EMAT test for predicting LV dysfunction. 
 
Peacock WF et al. (Peacock et al., 2006) studied 340 emergency department patients 
with suspected acute decompensated heart failure and found that S3 score was highly 
specific (94%) for acute decompensated heart failure and was valuable in 
combination with BNP values to improve the diagnostic accuracy in undifferentiated 
emergency department dyspenic patients.  
 
In the secondary analysis of HEARD-IT study, Collins SP et al. (Maisel et al., 2011) 
found in patients with "gray zone" BNP levels (100–500 pg/ml), acoustic 
cardiography increased diagnostic accuracy of acute heart failure from 47% to 69%.  
 
2.7 Hemodynamic correlations of acoustic cardiographic parameters 
Roos M et al. (Roos et al., 2006) investigated 17 patients with LVSD (defined as 
LVEF < 50%) at cardiac catheterization. It was found that there were strong 
associations between acoustic cardiographic parameters (S3 score, EMAT and LVST) 
and LVEDP, EF, and maximum contractility. 
 
In 161 patients with suspected or known cardiac disease, echocardiography and 
acoustic cardiography were performed. Zuber M et al. (Zuber et al., 2006) found 
acoustic cardiographic S3 score correlates with echocardiographic evidence of 
impaired LV function, and the EMAT/LVST ratio reflects reduced EF. 
 38 
 
In one study of 100 adult patients undergoing left heart catheterization, Moyers B et 
al. (Moyers et al., 2007) found EMAT (r = −0.51; p < 0.0001), EMAT/LVST (r = 
−0.41; p = 0.0001), and Q-S2 (r = −0.39; p = 0.0003) correlated with LVEF, but not 
with LVEDP. An abnormal EMAT ≥ 15 (odds ratio 1.38, p < 0.0001) and 
EMAT/LVST ≥ 0.40 (OR 1.13, p = 0.002) were associated with LV dysfunction. 
 
Efstratiadis S et al. (Efstratiadis and Michaels, 2008) compared %EMTA and 
invasive and echocardiographic parameters of LV contractility in 25 patients with 
heart failure. An abnormal %EMAT (%EMAT ≥ 0.15) correlated with a lower LVEF 
(50.9% ± 18.6% with normal EMAT vs 32.0% ± 10.9% with abnormal EMAT, p = 
0.015), end-systolic elastance (3.07 ± 1.56 mm Hg/mL vs 1.43 ± 0.83 mm Hg/mL, p 
= 0.018), and peak isovolumetric LV pressure at the end-diastolic volume (317 ± 90 
mm Hg vs 222 ± 67 mm Hg, p = 0.015). An abnormal %EMAT was associated with 
a higher end-systolic volume index (33.6 ± 29.3 mL/m2 vs 71.0 ± 35.8 mL/m2, p = 
0.011), end-diastolic volume index (61.2 ± 29.8 mL/m2 vs 100.3 ± 40.8 mL/m2, p = 
0.012), and dyssynchrony (26.1% ± 6.0% vs 31.5% ± 3.5%, p = 0.028). There was no 
difference in end-diastolic pressure (20.3 ± 7.9 mm Hg vs 21.4 ± 12.3 mm Hg, p = 
0.78). 
 
2.8 Prognostic value of acoustic cardiography 
In HEARD-IT study (Collins et al., 2009), S3 score were found to provide no 
significant independent prognostic information on 30-day (odds ratio 1.20; 95% CI, 
0.67–2.14) or 90-day events (odds ratio 1.22; 95% CI, 0.78–1.90). 
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In another study enrolling 45 patients admitted for acute heart failure, Chao T et al. 
(Chao et al., 2010) found that admission %EMAT and %PEP, pre-discharge %EMAT, 
and post-discharge %EMAT significantly predicted post-discharge cardiovascular 
events with hazard ratios and 95% CIs of 1.75 (1.13–2.70), 1.67 (1.02–2.70), 1.87 
(1.10–3.17) and 2.50 (1.58–3.97) per 1-SD increment, respectively. The predictions 
remained significant after adjustment for age, sex, LVEF, E/e′ by Doppler 
echocardiography, and BNP. 
 
2.9 Cardiac resynchronization therapy 
Optimization of pacemaker settings for cardiac resynchronization therapy (CRT) 
remains challenging and problematic. Several studies were conducted to evaluate the 
value of acoustic cardiography as a fast and more cost-efficient alternative to 
established echocardiographic imaging techniques for the optimization of CRT 
devices. 
 
Hasan A al et. (Hasan et al., 2006) reported one study involving 22 cases. The 
atrioventricular (AV) delays in 22 subjects with implanted CRT devices were 
independently optimized using echocardiography (Doppler transmitral flow) as well 
as acoustic cardiography, and the recommended settings from each method were later 
compared. Doppler echocardiography and acoustic cardiography recommendations 
matched within 17±16 milliseconds and gave a correlation coefficient of r = 0.90 
(p<0.001). In 17 of the 22 cases (77.3%), the difference between echocardiographic 
and acoustic cardiogram CRT optimization results was ≤ 20 milliseconds. 
Furthermore, the echocardiographic transmitral flow pattern was not significantly 
different for the setting independently chosen by the echocardiographic expert and 
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the acoustic cardiographer for the cases with a difference of > 20 milliseconds 
(22.7%). 
 
Zuber M et al. (Zuber et al., 2008) conducted another similar study of comparison of 
acoustic cardiography and echocardiography for optimizing pacemaker settings in 43 
patients with CRT. The correlation between the optimal AV delays determined by 
EMAT versus transmitral flow assessment was 0.86 (p < 0.001). The correlation 
between the optimal inter-ventricular (VV) delays determined by EMAT versus 
velocity time integral (VTI) was 0.58 (p < 0.05), perhaps due to the poor 
reproducibility of the VTI in LV outflow tract. 
 
Toggweiler S et al. (Toggweiler et al., 2007) reported another pilot study involving 
14 cases to determine the utility of acoustic cardiography for the optimization of AV 
and VV delays in CRT. Optimal AV/VV settings were determined based on the 
lowest EMAT. In comparison to "out-of-the-box" settings, AV/VV delay optimization 
with acoustic cardiography improved cardiac performance as indicated by significant 
changes in work capacity, maximum oxygen uptake, oxygen pulse, EF, end-systolic 
volume, and VTI l in LV outflow tract. 
 
2.10 Detection of ischemia 
Although the standard 12-lead ECG is considered as the gold standard to diagnose 
acute myocardial ischemia, nearly half of ECGs are non-diagnostic in patients who 
present with chest pain. Several studies were performed to investigate whether S3 




In a study (Lee et al., 2009) of 24 subjects undergoing non-emergent percutaneous 
coronary intervention (PCI), a new or increased-intensity S3 or S4 developed in 67% 
of patients during percutaneous coronary intervention induced ischemia. Ten (67%) 
of 15 patients without clinical ST criteria for ischemia also developed new or 
increased-intensity diastolic heart sounds. 
 
A prospective study (Lee et al., 2009) was performed in 21 subjects undergoing PCI 
who had both ST amplitude changes > 2 standard deviations above baseline on 
12-lead ECG. Electrocardiographic ST amplitude and diastolic heart sounds' changes 
occurred contemporaneously, shortly after coronary occlusion (mean onset from 
balloon inflation; ST changes, 21±17 seconds; S4, 25±26 seconds; S3, 45±43 
seconds). In 40% of patients, a new or increased S3 or S4 developed earlier than ST 
changes. Angina occurred in only 2 of the 21 subjects during ischemia with a mean 
onset time of 68 seconds. ST-segment changes resolved earliest (33 seconds after 
balloon deflation) while diastolic heart sounds (89±146 seconds) and angina 
(586±653 seconds) resolved later. 
 
Lee E et al. (Lee et al., 2009) conducted one prospective comparison study including 
19 subjects with ischemia induced by PCI and 18 subjects without coronary artery 
disease (CAD) or ischemic ECG evidence as control. Both S3 and S4 were shown to 
detect ischemia (p<0.05), independent of ST-T criteria. The detection of ischemia 




Zuber M et al. (Zuber and Erne, 2010) performed an explorative study in 59 patients 
with suspension of CAD referred for exercise tolerance test. Sensitivity/specificity of 
ST segment depression in the group was 29%/92%, whereas the most powerful 
acoustic cardiographic parameter was S4 score, with corresponding 
sensitivity/specificity of 53%/92%. 
 
Conclusions 
From all the previous studies done using acoustic cardiography (summarized in table 
2.1), several conclusions can be made. Firstly, acoustic cardiography is helpful in 
assisting auscultation of diastolic heart sounds and revealing the potential mechanism 
of their generation. Secondly, this technology can also detect heart failure/LV 
dysfunction or elevated LV filling pressure and augment the diastolic utility of BNP 
in heart failure patients with moderate elevated BNP. Thirdly, it is likely to be used as 
an alternative method to echocardiography in optimization of CRT. Lastly, acoustic 
cardiography may improve noninvasive diagnosis of myocardial ischemia by ECG 
alone. However, little work has been done detecting the different phenotypes of heart 
failure in particular the difficult group of patients who have heart failure with a 




Table 2. 1 Major studies of acoustic cardiography (listed in chronological order) 
Author Year Subjects Conclusions 
Marcus G et al. 
(Marcus et al., 
2005) 
2005 90 patients undergoing left-sided heart 
catheterization  
Neither S3 nor S4 is a sensitive marker of LV dysfunction. S3 
is specific for LV dysfunction and appears to be superior to 
the moderate specificity of S4. 
Collins SP et al. 
(Collins et al., 
2005) 
2005 1329 asymptomatic adults between the 
ages of 18 and 94. 
The prevalence of S3 decreases with age. An S4 is less 
common than previous studies suggested and its detection 
should not be ignored ever in the elderly. 
Collins SP et al. 
(Collins et al., 
2006) 
2006 343 ED patients with undifferentiated 
dyspnea 
S3 is highly specific for HF and is suited for use in 
combination with BNP to improve diagnostic accuracy in ED 
patients with dyspnea of unclear etiology. 
Marcus G et al. 
(Marcus et al., 
2006) 
2006 100 patients undergoing LV 
catheterization as well as 26 cardiology 
attendings, 18 cardiology fellows, 54 
internal medicine residents and 48 internal 
medicine interns. 
The S3 auscultated by more experienced physicians 
demonstrate fair agreement with acoustic cardiography. 
Although correlations were superior for acoustic 
cardiography, the associations between the S3 and abnormal 
markers of LV function improved with each level of 
experience. 
Roos M et al. 
(Roos et al., 2006) 
2006 17 patients with LVSD (defined as EF < 
50%).  
Acoustic cardiographic data can be used in the evaluation of 
patients with known or suspected LV dysfunction. 
Zuber M et al. 
(Zuber et al., 
2006) 
2006 161 patients with suspected or known 
cardiac disease 
S3 correlates with echocardiographic evidence of impaired LV 
function, and the EMAT/LVST ratio reflects reduced EF. 
Hasan A al et. 
(Hasan et al., 
2006) 
2006 22 cases with CRT It took less time for acoustic cardiography to make a 
recommendation, and acoustic cardiographic data trend is 
easier to interpret. 
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Author Year Subjects Conclusions 
Peacock WF et al. 
(Peacock et al., 
2006) 
2006 340 ED patients with suspected ADHF  S3 was highly specific for ADHF and was valuable in 
combination with BNP values to improve the diagnostic 
accuracy in undifferentiated ED dyspenic patients.  
Collins SP et al. 
(Collins et al., 
2006) 
2006 376 patients with suspected HF S3 presence is affected by prior treatment with diuretics or 
vasodilators. 
Zuber M et al. 
(Zuber et al., 
2007) 
2007 164 outpatients referred for 
echocardiographic evaluation for suspected 
HF 
Acoustic cardiographic data substantially improved the 
diagnostic evaluation of patients with non-diagnostic BNP. 
Toggweiler S et 
al. (Toggweiler et 
al., 2007) 
2007 14 cases with CRT AV and VV optimization by acoustic cardiography produces 
significant improvements in objective clinical and 
hemodynamic parameters in comparison to typical 
"out-of-the-box" settings. 
Zuber M et al. 
(Zuber et al., 
2007) 
2007 171 patients with possible chronic 
compensated or mildly decompensated HF 
as the learning population as well as 399 
patients with signs or symptoms of 
decompensated HF as the test population. 
Improved identification of LVSD and clinical HF can be 
achieved with acoustic cardiography 
Moyers B et al. 
(Moyers et al., 
2007) 
2007 100 adult patients undergoing left heart 
catheterization 
Acoustic cardiographic STIs are insensitive but highly 
specific for LV dysfunction. EMAT and EMAT/LVST 
provide diagnostic information independent of BNP for 
detecting LV dysfunction. 
Shapiro M, et al. 
(Shapiro et al., 
2007) 
2007 81 adult patients undergoing left heart 
catheterization 
The LV dysfunction index combining S3 sore and STI yielded 
superior test characteristics compared to the individual tests 
for the diagnosis of LV dysfunction. 
Efstratiadis S et al. 
(Efstratiadis and 
Michaels, 2008) 
2008 25 patients with HF An abnormal %EMAT was strongly associated with impaired 
LV contractility but had no association with LV filling 
pressures.  
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Author Year Subjects Conclusions 
Zuber M et al. 
(Zuber et al., 
2008) 
2008 43 cases with CRT Acoustic cardiography provides results similar to 
echocardiography but with improved reproducibility and ease 
of use. 
Roos M et al. 
(Roos et al., 2008) 
2008 108 patients who underwent elective 
diagnostic cardiac catheterization 
Acoustic cardiography outperformed both angiographic EF 
and QRS duration alone in detecting LVSD. 
Lee E et al. (Lee 
et al., 2009) 
2008 24 subjects undergoing non-emergent PCI The combined use of diastolic heart sounds and ECG may 
improve the noninvasive diagnosis of ischemia 
Shah SJ et al. 
(Shah et al., 2008) 
2008 90 participants undergoing left heart 
catheterization 
S4 is most likely generated from an abnormally stiff LV, 
supporting the concept that the S4 is a pathologic finding in 
older patients. 
Shah SJ et al. 
(Shah et al., 2008) 
2008 90 patients undergoing left-sided heart 
catheterization  
The most important determinants of the pathologic S3 are an 
increased deceleration rate of early mitral inflow, elevated LV 
filling pressures, and abnormal compliance of the myocardium 
as measured by tissue Doppler imaging. 
Gupta S et al. 
(Gupta and 
Michaels, 2009) 
2009 100 patients undergoing LV 
catheterization as well as 26 cardiology 
attendings, 18 cardiology fellows, 54 
internal medicine residents and 48 internal 
medicine interns. 
The S4 auscultated by cardiology attendings demonstrated 
superior diagnostic test characteristics compared with internal 
medicine house staff and cardiology fellows. Correlations 
between the S4 and measures of ventricular filling pressure 
were superior for acoustic cardiography compared to the 
auscultator groups. 
Collins SP et al. 
(Collins et al., 
2009) 
2009 124 patients with NSTEMI or acute 
decompensated HF and 91 patients 
referring to LV catheterization and 175 
ambulatory patients 
Acoustic cardiography predicted echocardiographic correlates 
of increased pressures with high accuracy. 
Collins SP et al. 
(Collins et al., 
2009) 
2009 995 dyspneic patients admitted in ED Acoustic cardiographic S3 was specific for ADHF and 
affected physician confidence but did not improve diagnostic 
accuracy for ADHF, largely because of its low sensitivity. S3 
provided no prognostic independent prognostic information. 
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Author Year Subjects Conclusions 
Lee E et al. (Lee 
et al., 2009) 
2009 21 subjects undergoing PCI A new or intensified S3 and/or S4 occurred 
contemporaneously with electrocardiographic changes during 
ischemia. S3 and S4 persisted longer than ST changes in the 
early detection following coronary reperfusion. 
Lee E et al. (Lee 
et al., 2009) 
2009 19 subjects with ischemia induced by PCI 
and 18 subjects without CAD or ischemic 
ECG evidence. 
Acoustic cardiography may augment the ECG detection of 
ischemia. 
Maisel AS et al. 
(Maisel et al., 
2011) 
2010 995 patients with dyspnea S3 assists with HF identification and complements the use of 
BNP in the gray zone. And its diagnostic/prognostic ability is 
largely unaffected by BMI and renal function. 
Michaels AD et al. 
(Michaels et al., 
2010) 
2010 90 adults referred for catheterization and 
35 subjects including 5 first-year medical 
students, 5 fourth-year medical students, 5 
interns, 5 medicine residents and 5 
cardiology fellows 
Viewing acoustic cardiography increased subjects' accuracy in 
detecting diastolic heart sounds, particularly among more 
experienced subjects. There was greater improvement for S4 
compared to S3. 
McCullough PA et 
al. (McCullough et 
al., 2010) 
2010 190 subjects with morbid obesity Acoustic cardiography was not helpful in assisting the 
cardiovascular examination of the morbidly obese. 
Taha N et al. 
(Taha et al., 2010) 
2010 44 patients referred for pacemaker 
optimization 
Comprehensive echocardiographic guided Biv pacemaker 
optimization produces significant improvement in Doppler 
echocardiographic hemodynamics, a reduction in S3 score, 
and an improvement in functional class in patients after CRT.  
Collins SP et al. 
(Collins et al., 
2010) 
2010 68 patients referred for elective left and 
right heart catheterization. 
The four variable model predicts elevated filling pressure with 
high specificity and an intermediate positive likelihood ratio. 
Dillier R et al. 
(Dillier et al., 
2010) 
2010 194 patients who underwent diagnostic 
cardiac catheterization. 39 of them had 
atrial fibrillation 
Acoustic cardiography can diagnose systolic dysfunction in 
atrial fibrillation. 
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Author Year Subjects Conclusions 
Kosmicki DL et 
al. (Kosmicki et 
al., 2010) 
2010 176 patients with ACS and/or ADHF and 
82 patients referred for left heart 
catheterization. 
This acoustic cardiographic model outperformed BNP alone 
for predicting LVSD. 
Zuber M et al. 
(Zuber and Erne, 
2010) 
2010 59 patients with suspension of CAD 
referred for ETT 
The use of acoustic cardiography alone during ETT or 
disjunctively with ST depression is a simple and convenient 
method to detect CAD, which is superior to ST depression on 
the standardized ECG. 
Chao T et al. 
(Chao et al., 2010) 
2010 45 patients hospitalized for AHFS EMAT measured during hospitalization is useful to predict 
cardiovascular outcomes in patients with AHFS independent 
of LVEF, E/e and NT-proBNP. 
Karabsheh S et al. 
(Karebsheh and 
Michaels, 2011) 
2011 83 patients undergoing coronary 
angiography 
The findings have implications for assessment of 
transmyocardial ischemia in patients with confounding ECG 
interpretation. 
Dillier R et al. 
(Dillier et al., 
2011) 
2011 67 heart failure patients and 63 
asymptomatic control subjects 
Heart failure patients exhibited little diurnal variation, 
indicating a constant stimulation of sympathetic tone. 
Dillier R et al. 
(Dillier et al., 
2011) 
2011 128 symptomatic subjects The nocturnal increase of S4 in the elderly reflects diastolic 
impairment. An S3 after 40 years old is a relatively 
uncommon finding. 
 
Abbreviations: LV = left ventricular; ED = emergency department; HF = heart failure; LVSD = left ventricular systolic dysfunction; EF 
= ejection fraction; ADHF = acute decompensated heart failure; NSTEMI = Non-ST segment elevation myocardial infarction; PCI = 
percutaneous coronary intervention; ACS = acute coronary syndrome; ETT = exercise tolerance test; CAD = coronary artery disease; 
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Chapter 3 Acoustic Cardiography Helps to Identify Heart Failure and Its 
Phenotypes 
Introduction 
Despite recent advances in its management, heart failure remains a major cause of 
disability and death and its prevalence is still increasing as the population ages 
(Roger et al., 2011). With an array of diagnostic tests, rapid and accurate bedside 
diagnosis of heart failure still remains challenging. It was reported that as many as 
10-20% of emergency department patients with acute decompensated heart failure 
were misdiagnosed (Dao et al., 2001; McCullough et al., 2002; Collins et al., 2006).  
 
Dyspnea is the most common presentation of heart failure, and it is also the common 
symptom of many other diseases, such as chronic obstructive pulmonary disease 
(COPD), pneumonia and anemia. Heart failure occurs most frequently in the elderly, 
a population often with similar comorbidities. Diagnosis of heart failure based on 
history and physical examination alone is often unreliable (Stevenson and Perloff, 
1989). Consequently, accurate and rapid diagnosis of heart failure can be difficult 
when heart failure coexists with these diseases. 
 
Over the past few years, there has been a growing recognition that a large number 
(more than 50%) of patients with heart failure have a relatively normal ejection 
fraction (EF), labeled as heart failure with normal (or preserved) ejection fraction 
(HFNEF) as opposed to heart failure with reduced ejection fraction (HFREF) (Paulus 
et al., 2007). Although the prognosis of patients suffering from HFNEF is equally 
bad as those suffering from HFREF, the epidemiology, clinical characteristics, and 
therapy of HFNEF are different from HFREF. Thus, it is necessary to differentiate 
 50 
these two phenotypes. 
 
B-type natriuretic peptide (BNP) is often used to evaluate patients with possible heart 
failure, but its frequently encountered intermediate “gray zone” between 100-500 
pg/ml limited its diagnostic utility (Maisel et al., 2002). Furthermore, BNP is 
sensitive to other biological factors, such as age, gender, weight, and renal function 
(Weinfeld et al., 1999). Likewise, elevated BNP levels can occur in other settings, 
such as pulmonary embolism and COPD (Hunt et al., 2009). All these limitations 
make it difficult to interpret BNP results during differential diagnoses. 
 
Echocardiography is a well validated resource to detect and evaluate left ventricular 
(LV) dysfunction (Cheitlin et al., 2003). However, this technology requires 
specialized training for image acquisition and interpretation and is not always readily 
available. 
 
In this study, we sought to determine whether this new technology could accurately 
identify heart failure and its phenotypes. 
 
Methods 
Participants and study design 
Our study population consisted of 3 separate cohorts including 94 patients with 
hypertension, 109 patients with HFNEF and 89 patients with HFREF. Patients' 
medical records had been reviewed to determine the diagnoses of heart failure or 
hypertension based on established criteria (McKee et al., 1971; Chobanian et al., 
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2003; Hunt et al., 2009). Heart failure patients with EF<50% and EF≥50% were 
categorized into HFREF and HFNEF groups, respectively. All the heart failure 
patients were enrolled from in-patients. Exclusion criteria for hypertension cohort 
included age < 18 years old, pregnancy, secondary hypertension with underlying 
causes, diabetes mellitus, known structural heart diseases, coronary heart disease, 
EF<50% and pacemaker implantation. Exclusion criteria for heart failure cohort 
included age < 18 years old, systolic blood pressure < 90 mmHg, mitral stenosis, 
constrictive pericarditis, use of mechanical ventilation and pacemaker implantation. 
Informed consent was obtained from each patient and the study was approved by 
local ethics committee of the institution. 
 
Echocardiography 
Echocardiography was performed (Vivid 7, Vingmed-General Electric, Horten, 
Norway, and IE33, Phillips, Andover, MA) in all patients of three groups. 
Investigators who interpreted echocardiographic findings were blinded to the clinical 
and acoustic cardiographic data. End-diastolic and end-systolic volumes were 
calculated using the biplane Simpson's method. And then these volumes were used to 
calculate left ventricular ejection fraction (LVEF). Early diastolic mitral annular 
velocity obtained by pulsed wave Doppler was used to determine e′ and ratio of E/e′. 
e′ is the peak early diastolic annular velocity and is measured at the septal wall at the 
base of the ventricle. e′ reflects early diastolic recoil and therefore the degree of 
ventricular suction and the rapid early diastolic filling.and is markedly reduced in 
heart failure of all forms. E is the peak early diastolic mitral inflow velocity and the 
ratio of E/e′ has been shown to correlate with end-diastolic pressure and can be 
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viewed as a broad measure of diastolic function. Higher values suggest a higher 
LVEDP and therefore worse LV diastolic filling (Nagueh et al., 1997). 
 
Acoustic cardiography 
Each subject underwent the acoustic cardiographic examination in supine position. 
Acoustic cardiographic raw data were transferred to Inovise Medical and were 
analyzed by the computerized algorithm for the measurement of heart sounds and 
related STIs. This algorithm has been validated by blinded interpretation of heart 
sound tracings by experts. And the relationship of these variables to hemodynamic 
measurements obtained by invasive and non-invasive methods were previously 
reported (Marcus et al., 2005; Roos et al., 2006). At least 3 examinations had been 
performed to each patient and the average values of each variable were used for 
analysis. 
 
The following acoustic cardiographic variables were evaluated in the present study: 
1. QR interval: the time from the Q wave onset to the peak of R wave (or S wave for 
QS morphologies). 
2. QT interval: the time from the Q wave onset to the end of the T wave.  
3. QTc interval: QT interval divided by the square root of the R to R interval 
(Bazett’s formula). 
4. QRS duration: the time from the QRS onset to QRS offset. 
5. Electromechanical activation time (EMAT): the time from the Q wave onset to the 
mitral component of the first heart sound (S1) (Figure 3.1). EMAT reflects the time 
required for LV to generate sufficient force to close the mitral valve.  
 53 
6. LV systolic time (LVST): the time from S1 to the second heart sound (S2) (Figure 
3.1). 
7. LV diastolic perfusion time (LDPT): the time from S2 to the next Q wave onset. 
8. S3 intensity: the measurement of the intensity of S3. 
9. S3 score: the probability that S3 exists. On the basis of timing, persistency, 
intensity, frequency of the sound, one value between 0 and 10 is reported. Values > 5 
indicate S3 is present. 
10. Systolic dysfunction index (SDI): SDI= exp (S3 score/10) x QRS duration x QR 
interval x %EMAT. The SDI value undergoes a nonlinear transformation and is 
mapped into a scale of 0 – 10, where SDI > 5 indicates EF < 50% and SDI > 7.5 
indicates EF < 35% and elevated LV filling pressure (Dillier et al., 2010). 
 
Due to the fact that EMAT, LVST and LDPT are influenced by heart rate, indices 
normalized by heart rate were used, and those were %EMAT, %LVST and %LDPT, 
respectively. To reduce the detrimental effect of unstable heart rate in patients with 
atrial fibrillation (AF), at least 5 examinations were performed in each AF patient 
and the average values were used. 
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Figure 3. 1 Schematic of normal and abnormal S3 and STIs. Those with heart failure 
may have S3, longer EMAT and shorter LVST.  
Abbreviations: ECG, electrocardiogram; Ao, aortic; LA, left atrial; LV, left 
ventricular; S1, the first heart sound; S2, the second heart sound; S3, the third heart 
sound; STIs: systolic time intervals; EMAT: electromechanical activation time; LVST: 
left ventricular systolic time. 
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Assessment of reproducibility  
Inter-operator reproducibility was assessed in 20 randomly selected patients 
involving 2 operators. Intra-class correlation coefficient (ICC) was used to determine 
consistency between operators. The reproducibility was considered excellent if ICC 
≥ 0.75 (Landis and Koch, 1977; Weir, 2005). 
 
Statistical analysis 
Data were described with mean and standard deviations for continuous variables and 
frequency and proportions for categorical variables. Comparisons among 
hypertension, HFNEF and HFREF groups were performed using one way analysis of 
variance for normal distributed data and Kruskal-Wallis H test for skewed data. 
Post-hoc Bonferroni test and Mann-Whitney U test were used for two-group 
comparison according to data type. Because of imbalanced age in these three groups, 
analysis of covariance was performed to determine cardiac function effect on 
%EMAT and SDI separately with age as covariate. Receiver operative characteristics 
(ROC) curves were generated to determine area under curve (AUC), sensitivity, 
specificity, positive likelihood ratio (LR+), and negative likelihood ratio (LR-) for 
predicting heart failure and its phenotypes. LR+ = sensitivity / (1-specificity), and 
LR- = specificity / (1-sensitivity). Unlike positive and negative predictive values, 
diagnostic inferences based on LR+ and LR- were independent of the prevalence of 
disease in the tested population. A two-sided p value less than 0.05 was considered to 
indicate statistical difference in all analyses. Statistical analyses were performed 
using SPSS, version 13.0 (SPSS, Inc., Chicago, Illinois). 
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Results 
Characteristics of study subjects 
Table 1 summarizes the demographic data, clinical history and medications of our 
patients who were subdivided into 3 groups according to cardiac function.  
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Demographics     
Age, year 54±10 77±10* 73±13*# <0.001 
Male, n (%) 46 (49) 46 (42) 66 (74) <0.001 
Clinical history     
Heart rate, bpm 65±10 77±16* 82±17* <0.001 
SBP, mmHg 134±17 148±30* 138±29# 0.003 
DBP, mmHg 81±13 74±19* 81±19# 0.019 
NYHA class, unitless NA 3.05±0.82 3.11±1.04 0.694 
Hypertension, n (%) 94 (100) 62 (56.9) 46 (51.7) 0.149 
DM, n (%) 0 44 (40.4) 26 (29.2) 0.041 
AF, n (%) 0 24 (22) 20 (20.2) 0.846 
CVD, n (%) 0 12 (11) 14 (15.7) 0.427 
PVD, n (%) 0 5 (4.6) 2 (2.2) 0.319 
IHD, n (%) 0 66 (60.6) 31 (34.8) 0.042 
COPD, n (%) 0 7 (6.4) 8 (9) 0.759 
Medications     
Diuretics, n (%) 35 (37.2) 66 (66.6) 65 (73) <0.001 
ACEIs, n (%) 26 (27.7) 45 (41.3) 43 (48.3) 0.003 
ARBs, n (%) 16 (17) 8 (7.3) 7 (7.9) 0.046 
CCBs, n (%) 55 (58.5) 34 (31.2) 8 (9) <0.001 
Beta-blockers, n (%) 42 (44.7) 44 (40.4) 45 (50.6) 0.318 









Statins, n (%) 16 (17) 39 (35.8) 38 (42.7) 0.013 
HT: hypertension; HFNEF: heart failure with normal ejection fraction; HFREF: heart 
failure with reduced ejection fraction; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; NYHA: New York Heart Association; DM: diabetes mellitus; AF: 
atrial fibrillation; CVD: cerebrovascular disease; PVD: peripheral vascular disease; 
IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; ACEI: 
angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CCB: 
calcium channel blocker; * p<0.05 for the comparison with patients in HT group; # 
p<0.05 for the comparison with patients in HFNEF group. 
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Acoustic cardiographic and echocardiographic characteristics  
Table 2 shows the acoustic cardiographic and echocardiographic data in the 3 groups. 
Compared with patients in hypertension group, patients in HFNEF group had a 
shorter QR and QT interval, lower %LDPT, greater %EMAT, S3 intensity and SDI. 
However, there was no statistical difference in S3 score between these 2 groups, 
which indicated that S3 intensity might be a more sensitive predictor of HFNEF 
compared with S3 score. Compared to patients with HFNEF, patients with HFREF 
had a longer QR, QTc, QRS interval, greater %EMAT, S3 intensity, S3 score, SDI, 
and lower %LDPT. Figure 3.2 reveals that %EMAT and SDI increased 
proportionally with the exacerbation of cardiac function. Both were largest in 
HFREF patients, intermediate in HFNEF patients, and smallest in hypertensive 
patients. 
 
Patients in HFNEF group had a lower LV end diastolic volume (LVEDV), LVEF, e′ 
velocity, and higher mitral E velocity, mitral A velocity and E/e′ ratio as compared 
with those of hypertension group. Likewise, patients in HFREF group had a larger 
LVEDV, LV end systolic volume (LVESV), lower LVEF, mitral A velocity, e′ 
velocity, higher E/A, E/e′ ratio and shorter E wave deceleration time as compared to 
those in HFNEF group.
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Acoustic cardiography     
QR interval, ms 40±5 39±8* 45±14*# <0.001 
QTc interval, ms 418±25 415±35 427±39# <0.001 
QT interval, ms 410±36 387±47* 394±49* 0.002 
QRS duration, ms 93±14 102±29 117±32*# <0.001 
%EMAT, % 8.97±1.9 12.21±3.05* 15.1±3.65*# <0.001 
%LVST, % 37.64±4.13 39.06±5.69 39.74±5.44* 0.027 
%LDPT, % 53.38±4.97 48.52±8.45* 45.29±7.66*# <0.001 
S3 intensity, unitless 0.32±0.27 0.54±0.57* 0.66±0.54*# <0.001 
S3 score, unitless 3.25±1.34 3.31±1.67 4.63±2.09*# <0.001 
SDI, unitless 2.09±1.09 3.49±1.91* 5.71±2.17*# <0.001 
Echocardiography     
LVEDV, mL 80±17 66±26* 135±55*# <0.001 
LVESV, mL 29±8 26±11 93±45*# <0.001 
LVEF, % 64.5±5.5 60.2±6.2* 32.8±9.1*# <0.001 
E, m/s 0.71±0.16 0.91±0.39* 0.95±0.38* <0.001 
A, m/s 0.72±0.16 0.97±0.26* 0.66±0.31# <0.001 
E/A ratio 1.04±0.31 0.82±0.36 1.71±1.08*# <0.001 
DT, ms 214±49 227±87 161±53*# <0.001 
Septal e′, cm/s 7.14±2.06 5.02±1.74* 3.76±1.59*# <0.001 
E/e′ ratio 10.87±4.71 16.97±6.62* 28.04±11.44*# <0.001 
Abbreviations: HT: hypertension; HFNEF: heart failure with normal ejection fraction; 
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HFREF: heart failure with reduced ejection fraction; %LDPT: left ventricular 
diastolic perfusion time normalized by heart rate; %EMAT: electromechanical 
activation time normalized by heart rate; %LVST: left ventricular systolic time 
normalized by heart rate; S3: the third heart sound; SDI: systolic dysfunction index; 
LVEDV: left ventricular end diastolic volume; LVESV: left ventricular end systolic 
volume; LVEF: left ventricular ejection fraction; E: early diastolic mitral inflow 
velocity; A: late diastolic mitral inflow velocity; DT: deceleration time of mitral E 
velocity; e′: early diastolic mitral annular velocity; * p<0.05 for the comparison with 






Figure 3. 2 The means and 95% confidence intervals of %EMAT (A) and SDI (B) in 
patients with HT, HFNEF and HFREF.  
Abbreviations: %EMAT: electromechanical activation time normalized by heart rate; 
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SDI, systolic dysfunction index; HT: hypertension; HFNEF, heart failure with normal 
ejection fraction; HFREF, heart failure with reduced ejection fraction. 
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Diagnostic characteristics of acoustic cardiography  
Table 3 represents the ROC curves analyses of various acoustic cardiographic 
parameters and E/e′ to detect HFNEF and HFREF. It lists the AUC, cut-off values 
with specificity of 90%, corresponding sensitivity, LR+ and LR- of each parameter in 
the diagnostic test. For detection of HFNEF, %EMAT outperformed all the other 
acoustic cardiographic parameters with a value > 11.54% that yielded 0.83 AUC, 
55% sensitivity, 90% specificity, 5.69 LR+ and 0.5 LR-. Similarly, an E/e′ > 15 
yielded 0.84 AUC, 55% sensitivity, 90% specificity, 5.58 LR+ and 0.5 LR-. 
 
On the other hand, SDI was the best predictor to detect HFREF, and an SDI > 5.43 
yielded 0.81 AUC, 53% sensitivity, 91% specificity, 5.61 LR+ and 0.52 LR-. 
Meanwhile, an E/e′ > 26 could detect HFREF with 0.83 AUC, 49% sensitivity, 91% 
specificity, 5.33 LR+ and 0.57 LR-. Figure 3.3 shows the ROC curves of %EMAT in 
detection of HFNEF and SDI in detection of HFREF. 
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Table 3. 3 Performances of acoustic cardiographic parameters and E/e′ to detect HFNEF and HFREF 
For HFNEF For HFREF Parameters 









QR interval 0.38 (0.30-0.46) 44ms 13 90 1.33 0.96 0.62 (0.54-0.71) 46ms  39  90  3.89  0.68 
QT interval 0.35 (0.28-0.43) 459ms 6 90 0.67 1.04 0.54 (0.46-0.62) 442ms  17  90  1.67  0.92 
QTc interval 0.47 (0.39-0.55) 449ms 17 90 1.72 0.92 0.61 (0.52-0.69) 462ms  20  90  2.00  0.89 
QRS 
duration 0.56 (0.48-0.63) 104ms 31  90  3.25 0.76 0.65 (0.58-0.73) 143ms  25  90  2.45  0.84 
%EMAT 0.83 (0.77-0.89) 11.54% 55  90  5.69 0.50 0.74 (0.67-0.80) 15.56% 43  90  4.19  0.64 
%LVST 0.60 (0.52-0.68) 43.93% 18  90  1.83 0.91 0.52 (0.43-0.60) 46.11% 10  90  0.99  1.00 
%LDPT 0.29 (0.22-0.37) 59.29% 7  90  0.78 1.02 0.38 (0.30-0.46) 57.19% 2  90  0.21  1.09 
S3 intensity 0.63 (0.55-0.70) 0.50  30  90  3.16 0.77 0.62 (0.54-0.70) 1.32  9  90  0.90  1.01 
S3 score 0.48 (0.40-0.56) 4.60  17  90  1.82 0.91 0.69 (0.62-0.77) 5.41  34  90  3.34  0.74 
SDI 0.78 (0.71-0.84) 3.26  42  90  4.34 0.65 0.81 (0.75-0.87) 5.43  53  91  5.61  0.52 
E/e′ ratio 0.84 (0.78-0.90) 15  55  90  5.58 0.50 0.83 (0.76-0.89) 26  49  91  5.33  0.57 
 66 
Abbreviations: HFNEF: heart failure with normal ejection fraction; HFREF: heart failure with reduced ejection fraction; AUC: area 
under curve; CI: confidence interval; LR+: positive likelihood ratio; LR-: negative likelihood ratio; %LDPT: left ventricular diastolic 
perfusion time normalized by heart rate; %EMAT: electromechanical activation time normalized by heart rate; %LVST: left ventricular 
systolic time normalized by heart rate; S3: the third heart sound; SDI: systolic dysfunction index; E: early diastolic mitral inflow 






Figure 3. 3 Receiver operating characteristics curves of %EMAT for differentiating 
HFNEF from hypertension (A) and SDI for HFREF from HFNEF (B).  
Abbreviations: %EMAT: electromechanical activation time; SDI, systolic 
dysfunction index; HFNEF, heart failure with normal ejection fraction; HFREF, heart 
failure with reduced ejection fraction.
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Analysis of covariance results 
We found that %EMAT was a robust predictor for HFNEF after controlling for age 
(F = 33.92; P < 0.001). Similar results were observed with SDI for detection of 
HFREF (F = 47.33; P < 0.001). 
 
Inter-operator reproducibility 
ICCs for %EMAT and SDI were 0.83 (95% confidence interval [CI], 0.61-0.93) and 
0.87 (95% [CI], 0.71-0.95), respectively. 
 
Discussion 
Our study showed acoustic cardiography could detect heart failure and its phenotypes 
with similar diagnostic accuracy to E/e′ ratio. In the previous studies, other authors 
had showed that acoustic cardiography could be used as a non-invasive method to 
detect LV systolic dysfunction (Moyers et al., 2007; Shapiro et al., 2007; Zuber et al., 
2007; Roos et al., 2008; Dillier et al., 2010; Kosmicki et al., 2010) and increased LV 
filling pressure (Collins et al., 2009; Collins et al., 2010). However, the ability of 
acoustic cardiography in detection of HFNEF and discrimination of HFNEF and 
HFREF has not been explored. 
 
Owing to a lack of sufficient specific symptoms and signs and to a more 
heterogeneous etiopathology, the diagnosis of HFNEF is more challenging compared 
to HFREF. Besides systolic ventricular and arterial stiffening, diastolic LV 
dysfunction is considered to be the most common cause of HFNEF (Kindermann et 
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al., 2008). Thus, the key point in diagnosis of HFNEF is how to evaluate diastolic 
dysfunction. E/e′ ratio obtained by pulsed-wave Doppler is associated with LV filling 
pressure (Ommen et al., 2000) and is used as a predictor for LV diastolic dysfunction 
(Paulus et al., 2007; Nagueh et al., 2009). Previous studies have shown that %EMAT 
correlated closely with LV systolic function (Roos et al., 2006; Efstratiadis and 
Michaels, 2008; Roos et al., 2008). Our finding that %EMAT is the best predictor for 
HFNEF corroborates our concept that systolic function is not entirely normal in 
HFNEF when measures other than EF are used (Kindermann et al., 2008; Tan et al., 
2009; Yamamoto et al., 2009; Yip et al., 2009). We propose that %EMAT could be 
used as a potential surrogate measurement of E/e′ ratio in diagnosis of HFNEF. 
 
However, SDI was a better predictor for discriminating HFREF from HFNEF than 
%EMAT. This is mainly because QR interval, QRS duration, S3 score and %EMAT 
in HFREF group all increased compared with in HFNEF group, resulting in a marked 
increase in SDI. However, there were no significant differences in QRS duration, S3 
score between the Hypertension and HFNEF groups, which attenuated the diagnostic 
performance of SDI in discriminating HFNEF from hypertension without heart 
failure.  
 
Although a comprehensive echocardiographic examination is of great help in 
identification of heart failure and its phenotypes, this technology is time consuming 
and needs considerable specialized skill for image acquisition and interpretation. 
Moreover, the echocardiographic findings are frequently inconclusive in some 
patients. For instance, 8 <E/e′<15 is only suggestive of diastolic LV dysfunction and 
additional investigations are required for diagnostic evidence (Paulus et al., 2007). 
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Since first described by Potain in the 1880s, the auscultated S3 has been an important 
and specific indicator for heart failure, especially in patients older than 40 years old. 
However, the low sensitivity (Marcus et al., 2005; Shah and Michaels, 2006) and 
poor inter-observer agreement regarding auscultation among physicians (Ishmail et 
al., 1987) limit its clinical application. 
 
STIs are other well-validated indicators of heart failure. Prior studies proved that 
STIs correlated closely with LV function, such as angiographically determined 
LVEDV (Garrard et al., 1970), LVEF (Garrard et al., 1970), and cardiac output with 
indicator-dilution technique (Weissler et al., 1968). Whereas the complicated 
measurement of STIs that involved ECG, phonocardiography and carotid pulse 
tracing made a rapid diagnosis impossible (Lewis et al., 1977). 
 
Several limitations of this study need to be considered. Firstly, the 3 groups in our 
study are not age-matched. However, we found that %EMAT and SDI were still 
robust predictors for heart failure detection after controlling for age with analysis of 
covariance. We also performed an age-balanced subgroup analysis including 22 
hypertensive patients (mean age = 64±3 years) and 20 HFNEF patients (mean age = 
64±3 years), and we found that %EMAT in HFNEF group was greater than in 
hypertension group (p < 0.001). In another age-balanced subgroup analysis which 
included 22 hypertensive patients (mean age = 64±3 years) and 18 HFREF patients 
(mean age = 64±3 years), we found that SDI in HFREF group was greater than in 
hypertensive group (p < 0.001). Secondly, Heart failure cohort in our study was 
selected from in-patients. Although most of them were clinically stable when 
enrolled, their results may not be applicable to all chronic heart failure patients. 
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Thirdly, heart failure patients with AF were not excluded from our study. In order to 
reduce the effect of irregular heart rate, more examinations were performed and the 
average values were used for analysis. Dillier R et al also demonstrated that acoustic 
cardiography could be used for diagnosis of left ventricular dysfunction in AF 
(Dillier et al., 2010). Fourthly, patients with left bundle branch block (LBBB) were 
not excluded from this study. In subgroup analysis of patients without LBBB 
(including 91 hypertension, 84 HFNEF and 55 HFREF patients), %EMAT and SDI 
were still the best predictor to diagnose HFNEF (AUC, 0.84; 95% CI, 0.78–0.90) and 
HFREF (AUC, 0.82; 95% CI, 0.75–0.89). Meanwhile, in subgroup analysis of 
patients with LBBB, (only including 25 HFNEF and 34 HFREF patients, because 
only 3 hypertension patients had LBBB), SDI outperformed the other acoustic 
cardiographic parameters in detection of HFREF (AUC, 0.77; 95% CI, 0.63–0.91). 
Lastly, there are also other factors independent of LV function that can affect acoustic 
cardiographic variables, such as mitral regurgitation and medications. The patient 
diversity in current study may also reduce the statistical power of the analysis. We 
tried to test the current technology in a patient pool that was likely to be 
representative of the real clinical picture so that the results would be clinically 





Chapter 4 Rapid Bedside Identification of High-Risk Population in Heart 
Failure with Reduced Ejection Fraction by Acoustic Cardiography 
Introduction 
Heart failure incidence approaches 10 per 1000 population after 65 years of age and 
about 50% of patients diagnosed with heart failure will die within 5 years (Roger et 
al., 2011). Myocardial systolic performance (left ventricular ejection fraction [LVEF] 
assessed by echocardiography) has long been an important prognosticator of poor 
outcomes in heart failure with reduced EF (HFREF). In addition, diastolic 
dysfunction is also common in HFREF and contributes to its signs and symptoms, 
irrespective of the presence or severity of systolic dysfunction. The presence of 
restrictive LV filling which indicates the most severe form of diastolic dysfunction, is 
also independently associated with compromised survival in HFREF patients (2008). 
Rapid identification of the degree of systolic and diastolic dysfunction in HFREF 
patients by echocardiography is therefore essential for appropriate treatment but the 
exam is often not readily available to the general physicians who are looking after 
these patients. 
 
In the previous study we have demonstrated the feasibility of rapid bedside diagnosis 
of HFREF by acoustic cardiography (Wang et al., 2012). Whether this novel 
technology could be useful in further identifying high-risk population in HFREF 
remains unknown. In this next study, we aimed at assessing whether acoustic 
cardiography could identify patients with severe systolic dysfunction (EF ≤ 35%) or 
severe diastolic dysfunction (restrictive filling pattern), that is a population with 





Our study population consisted of 94 hypertensive patients without heart failure and 
127 HFREF patients. Patients’ medical records had been reviewed to determine the 
diagnoses of heart failure or hypertension based on the established criteria (McKee et 
al., 1971; Chobanian et al., 2003; Hunt et al., 2009). All the heart failure patients 
were enrolled from in-patients. Exclusion criteria were as in our previous study. 
 
Echocardiography 
A complete 2-dimensional and Doppler echocardiographic examination was 
performed (Vivid 7, Vingmed-General Electric, Horten, Norway, and IE33, Phillips, 
Andover, MA) in all participants. Investigators who interpreted echocardiographic 
findings were blinded to the clinical and acoustic cardiographic data. LV 
end-diastolic (LVEDV) and LV end-systolic volumes (LVESV) were measured and 
LVEF was calculated using the biplane Simpson's method. Early diastolic mitral 
annular velocity (e′) was obtained by pulsed wave Tissue Doppler imaging. 
Trans-mitral flow velocities were measured by placing a 2mm size sample volume of 
pulsed wave Doppler at the tip of mitral valve leaflets from the apical 4-chamber 
view. Peak early diastolic velocity (E), peak atrial filling velocity (A), E/A ratio, E 
wave deceleration time (DT) and isovolumic relaxation time (IVRT) were measured 
from the LV filling recordings. The E/e′ ratio which reflected LV filling pressure was 
calculated. The LV filling pattern was characterized as a normal pattern, an abnormal 
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relaxation pattern (mild diastolic dysfunction), a pseudonormal pattern (moderate 
diastolic dysfunction) or a restrictive filling pattern (severe diastolic dysfunction), as 
described previously (Nishimura and Tajik, 1997; Oh et al., 1997; Yamamoto et al., 
1997). An abnormal relaxation pattern was characterized by a prolonged DT 
(>240ms), a reversed E/A ratio and a prolonged IVRT (>100ms). A restrictive filling 
pattern was characterized by a short DT (<140ms), a large E/A ratio (>2) and a short 
IVRT (<70ms). A pseudonormal pattern was defined by a relatively normal DT 
(140–240ms), a reversed pulmonary venous flow pattern with predominant systolic 
forward rather than diastolic flow, and a pulmonary venous atrial reversal wave 
duration that is 30ms longer than the mitral A wave. Subjects with 1 criterion for 
moderate or severe diastolic dysfunction or those whose parameters were borderline 
and suggestive of but not definitive for diastolic dysfunction were classified as 
indeterminate (Redfield et al., 2003). 
 
Acoustic cardiography 
In brief, please refer to methods section in chapter 3. 
 
Assessment of reproducibility  
In brief, please refer to methods section in chapter 3. 
 
Statistical analysis 




Baseline characteristics of study subjects 
94 hypertensive and 127 HFREF patients were enrolled into this study. Table 4.1 
summarized the demographic data, clinical history and medications of our study 
subjects.   
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Demographics    





Male, n (%) 46 (48.9) 91 (71.7) <0.001 
Clinical history    
Heart rate, bpm 65±10 83±17 <0.001 
SBP, mmHg 134±17 138±29 0.258 
DBP, mmHg 81±13 80±18 0.616 
NYHA class, unitless NA 3.05±1.03 NA 
HT, n (%) 94 (100) 66 (52) <0.001 
DM, n (%) 0 36 (28.3) <0.001 
AF, n (%) 0 31 (24.4) <0.001 
CVD, n (%) 0 19 (15) <0.001 
PVD, n (%) 0 1 (0.8) 0.371 
IHD, n (%) 0 40 (31.5) <0.001 
COPD, n (%) 0 13 (10.2) <0.001 
Medications    
Diuretics, n (%) 35 (37.2) 89 (70.1) <0.001 
ACEIs, n (%) 26 (27.7) 63 (49.6) <0.001 
ARBs, n (%) 16 (17) 10 (7.9) 0.052 
CCBs, n (%) 55 (58.5) 13 (10.2) <0.001 








Aspirin, n (%) 5 (5.3) 81 (63.8) <0.001 
Statins, n (%) 16 (17) 49 (38.6) 0.019 
Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; 
NYHA = New York Heart Association; DM = diabetes mellitus; AF = atrial 
fibrillation; CVD = cerebrovascular disease; PVD = peripheral vascular disease; IHD 
= ischemic heart disease; COPD = chronic obstructive pulmonary disease; ACEI = 
angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; 
CCB = calcium channel blocker. 
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Acoustic cardiographic and echocardiographic characteristics 
Table 4.2 represented the acoustic cardiographic and echocardiographic data of the 2 
patient groups. Regarding acoustic cardiographic parameters, HFREF patients had a 
longer QR interval, QRS duration, shorter QT interval, higher %EMAT, %LVST, S3 
score, SDI, and lower %LDPT as compared to those of hypertensive group. As for 
echocardiographic measurements, HFNEF group had a larger LVEDV, LVESV, 
lower LVEF, higher E velocity, E/e′ and E/A ratio, lower A velocity, e′ velocity, 
longer DT  and shorter IVRT than hypertensive group. Of the 127 HFREF patients, 
112 (88.2%) were classified as having diastolic dysfunction and 15 (11.8%) as 
indeterminate. The prevalence of diastolic dysfunction is higher in HFREF patients 
than in hypertensive patients. 
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Acoustic cardiography    
QR interval, ms 40±5 46±17 <0.001 
QRS duration, ms 93±14 119±32 <0.001 
QT interval, ms 410±36 391±50 <0.001 
%EMAT, % 8.97±1.89 15.32±3.66 <0.001 
%LVST, % 37.66±4.12 39.7±5.34 0.002 
%LDPT, % 53.36±4.94 45.03±7.57 <0.001 
S3 score 3.25±1.33 4.92±2.18 <0.001 
SDI 2.08±1.09 6.06±2.11 <0.001 
Echocardiography    
LVEDV, ml 81±17 136±56 <0.001 
LVESV, ml 29±8 94±47 <0.001 
LVEF, % 65±6 33±9 <0.001 
E, m/s 0.71±0.16 0.96±0.34 <0.001 
A, m/s 0.72±0.16 0.63±0.3 0.015 
E/A 1.04±0.31 1.96±1.39 <0.001 
DT, ms 214±49 158±56 <0.001 
IVRT, ms 88±17 82±26 <0.001 
e′, cm/s 7.14±2.06 3.95±1.64 <0.001 
E/e′ 10.87±4.71 27.19±12.24 <0.001 
Diastolic filling pattern    








Abnormal relaxation, n (%) 35 (37.2) 22 (17.3) 
Pseudonormal, n (%) 24 (25.5) 35 (27.6) 
Restrictive, n (%) 0 (0) 55 (43.3) 
Indeterminate, n (%) 0 (0) 15 (11.8) <0.001 
Abbreviations: %EMAT = electromechanical activation time normalized by heart 
rate; %LVST = left ventricular systolic time normalized by heart rate; %LDPT = left 
ventricular diastolic perfusion time normalized by heart rate; S3 = the third heart 
sound; SDI = systolic dysfunction index; LVEDV = left ventricular end diastolic 
volume; LVESV = left ventricular end systolic volume; LVEF = left ventricular 
ejection fraction; E = early diastolic mitral inflow velocity; A = late diastolic mitral 
inflow velocity; DT = deceleration time of mitral E velocity; IVRT = isovolumic 
relaxation time; e′ = early diastolic mitral annular velocity. 
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Table 4.3 represented the acoustic cardiographic and echocardiographic data of 4 
subgroups defined according to the degree of systolic and diastolic dysfunction. 
Compared with HFREF patients with LVEF >35% but less than 50%, those with 
EF≤35% were younger, had a longer QR interval, QRS duration, higher %EMAT, S3 
score, SDI, E/A ratio, larger LVEDV, LVESV, lower LVEF and A velocity. Compared 
with HFREF patients without severe diastolic dysfunction (i.e. patients with a normal, 
abnormal relaxation pattern and or pseudonormal filling pattern), those with severe 
diastolic dysfunction were younger, had a higher S3 score, E velocity, SDI, E/e′ and 




Table 4. 3 Demographic and clinical characteristics in the four subgroups 
 Degree of systolic dysfunction  Degree of diastolic dysfunction  
Variable 
35% < EF < 50% 
(N=57) 


















Male, n (%) 40 (70.2) 51 (72.9) 0.739 38 (69.1) 42 (73.7) 0.591 
Heart rate, bpm 82±19 84±15 0.666 83±16 82±17 0.794 
QR interval, ms 41±12 50±20 0.002 45±15 48±20 0.278 
QRS duration, ms 109±30 127±32 0.001 118±33 121±33 0.558 
QT interval, ms 385±51 395±48 0.273 390±46 393±51 0.723 
%EMAT, % 14.57±4 15.94±3.26 0.036 15.13±3.72 15.22±3.62 0.897 
%LVST, % 39.04±5.31 40.24±5.34 0.209 39.76±5.09 39.36±5.62 0.691 
%LDPT, % 46.4±8.24 43.91±6.83 0.064 45.15±7.75 45.46±7.48 0.830 
S3 score 4.27±2.09 5.44±2.12 0.002 3.95±1.9 5.86±2.04 <0.001 
SDI 4.95±1.87 6.98±1.84 <0.001 5.48±2.01 6.53±2.11 0.010 
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LVEDV, ml 104±38 163±55 <0.001 130±51 150±61 0.061 
LVESV, ml 61±25 121±44 <0.001 86±42 106±51 0.028 
LVEF, % 42±4 27±7 <0.001 35±8 31±10 0.009 
E, m/s 0.94±0.39 0.98±0.31 0.585 0.84±0.34 1.06±0.25 <0.001 
A, m/s 0.71±0.3 0.57±0.3 0.038 0.8±0.24 0.48±0.27 <0.001 
E/A 1.59±1.37 2.21±1.37 0.039 1.03±0.55 2.72±1.41 <0.001 
DT, ms 169±61 150±50 0.065 183±64 133±34 <0.001 
IVRT, ms 84±27 80±25 0.353 89±27 76±24 0.007 
e′, cm/s 3.81±1.26 4.06±1.9 0.416 4.2±1.9 3.7±1.24 0.102 
E/e′ 26.85±12.86 27.47±11.81 0.786 21.29±6.88 31.83±13.26 <0.001 
Abbreviations: %EMAT = electromechanical activation time normalized by heart rate; %LVST = left ventricular systolic time 
normalized by heart rate; %LDPT = left ventricular diastolic perfusion time normalized by heart rate; S3 = the third heart sound; SDI = 
systolic dysfunction index; LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; LVEF = left 
ventricular ejection fraction; E = early diastolic mitral inflow velocity; A = late diastolic mitral inflow velocity; DT = deceleration time 
of mitral E velocity; IVRT = isovolumic relaxation time; e′ = early diastolic mitral annular velocity. 
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Diagnostic test characteristics of acoustic cardiography 
SDI significantly differentiated HFREF from hypertension (area under curve [AUC], 
0.97; 95% confidence interval [CI], 0.95–0.99) with an SDI > 3.27 that yielded 93% 
sensitivity and 91% specificity. In subgroup analysis with reference to systolic 
dysfunction, SDI is the best predictor to discriminate (AUC, 0.79; 95% CI, 0.71–0.87) 
patients with lower EF (EF ≤ 35%) from those with moderate EF (35% < EF < 50%) 
with an SDI > 5.16 that yielded 85% sensitivity, 64% specificity, 2.34 PLR, 0.23 
NLR. In subgroup analysis regarding diastolic dysfunction, S3 score outperformed 
the other acoustic cardiographic parameters to detect severe diastolic dysfunction, 
and an S3 score > 4.67 identified patients with restrictive filling pattern with 0.76 
AUC (95% CI, 0.67–0.84), 70% sensitivity, 73% specificity, 2.57 PLR, 0.41 NLR. 
On the other hand, E/e′ detected severe diastolic dysfunction with higher specificity 
but lower sensitivity in our study. (Table 4.4) Figure 4.1 shows the ROC curves of 
SDI in detection of HFREF (A) and patients with lower EF (B) as well as S3 score in 
detection of patients with severe diastolic dysfunction (C). 
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Table 4. 4 Diagnostic test characteristics of acoustic cardiography and E/e′ in detection of severe systolic and diastolic dysfunction in 
HFREF 
Detecting EF ≤ 35% Detecting restrictive filling pattern Parameters 









%EMAT 0.65 (0.55-0.75) 
13.14 83 46 1.52 0.38 0.50 
(0.39-0.61) 
9.72 95 13 1.08 0.42 
S3 score 0.67 (0.57-0.76) 
4.12 76 60 1.87 0.41 0.76 
(0.67-0.84) 
4.67 70 73 2.57 0.41 
SDI 0.79 (0.71-0.87) 
5.16 85 64 2.34 0.23 0.65 
(0.54-0.75) 
7.31 42 83 2.42 0.70 
E/e′ ratio 0.54 (0.43-0.64) 
16.45 91 21 1.15 0.44 0.76 
(0.67-0.85) 
31.17 46 95 8.29 0.58 
Abbreviations: HFREF=heart failure with reduced ejection fraction; %EMAT = electromechanical activation time normalized by heart 























































Figure 4. 1 ROC curves of SDI in detection of HFREF (A) and patients with lower 
EF (B) as well as S3 score in detection of patients with severe diastolic dysfunction 
(C) 
Abbreviations: ROC = receiver operating characteristics; SDI = systolic dysfunction 
index; EF = ejection fraction. 
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Analysis of covariance results 
SDI was the predictor for heart failure (F = 260.81, p < 0.001) and severe systolic 
dysfunction (F = 25.31, p < 0.001) after controlling for age. Similar results were 




ICCs for SDI and S3 score were 0.87 (95% CI, 0.71–0.95) and 0.77 (95% CI, 
0.50–0.90), respectively.  
 
Discussion 
This study shows that SDI differentiated HFREF significantly from hypertension and 
identified patients with severe systolic dysfunction. On the other hand, S3 score 
outperformed all the other acoustic cardiographic parameters in detecting HFREF 
patients with severe diastolic dysfunction. In the previous studies, other authors had 
reported that acoustic cardiography could be used as a non-invasive method to detect 
LV systolic dysfunction (Moyers et al., 2007; Shapiro et al., 2007; Zuber et al., 2007; 
Roos et al., 2008; Dillier et al., 2010; Kosmicki et al., 2010; Wang et al., 2012) and 
increased LV filling pressure (Collins et al., 2009; Collins et al., 2010). However, the 
ability of acoustic cardiography in discriminating heart failure patients with severe 
systolic or diastolic dysfunction has not been explored previously. 
 
The optimal management of heart failure requires not only rapid and accurate 
diagnosis, but also reliable assessment of degree of LV functional impairment. 
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Nearly all patients with systolic dysfunction have some degree of concomitant 
diastolic dysfunction, specially, impaired relaxation and variable decreases in 
ventricular compliance (Nishimura and Tajik, 1997). Both systolic and diastolic 
dysfunction were predictive of subsequent adverse events and identification of 
particular subgroups or phenotypes can lead to specific and effective therapy. It has 
been suggested that up to 50% heart failure patients admitted into hospital are low 
risk and may be candidates for outpatient therapy. This represents a major potential 
saving of costs (Butler et al., 1998; Graff et al., 1999). Thus, a rapid diagnosis and 
risk stratification tool is vital in heart failure management. 
 
Echocardiography is a standard method for evaluation of LV function. Although 
being readily available, echocardiography does require high skills in image 
acquisition and interpretation. Other imaging modalities like radionuclide scanning 
and cardiac magnetic resonance are often prohibitive as initial tests in the emergency 
department due to lack of immediate availability and cost. 
 
STIs (Weissler et al., 1968; Weissler et al., 1969; Garrard et al., 1970) and S3 
(Stefadouros and Little, 1980; Patel et al., 1993; Mehta and Khan, 2004) historically 
have long been used as clinical predictors for heart disease, with diagnostic and 
prognostic importance (Drazner et al., 2001; Drazner et al., 2003). Studies in recent 
decades on alterations in cardiac performance of heart failure have focused largely on 
measures of flow, pressure and cardiac chamber volume while changes in the STIs 
and S3 have received relatively less attention. Reasons for this situation are 
multi-factorial but can be largely attributed to the complicated procedure of STIs 
measurements (Lewis et al., 1977) as well as the low sensitivity and poor 
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inter-observer agreement regarding S3 auscultation (Ishmail et al., 1987; Lok et al., 
1998).  
 
Due to its inexpensive, noninvasive and easy-to-use characteristics, acoustic 
cardiography has another obvious advantage that multiple observations can be 
performed. This allows an opportunity to assess changes of clinical status in heart 
failure patients and their response to therapeutic interventions, which will facilitate 
timely recognition and treatment of those at significant risk for morbidity and 
mortality.  
 
Several limitations of our study need to be considered. Firstly, the 2 groups in our 
study were not age-matched. However, we found that SDI and S3 score were still 
robust predictors for detection of severe systolic and diastolic dysfunction after 
controlling for age with analysis of covariance. In an age-balanced subgroup analysis 
which included 22 hypertensive patients (mean age = 64±3 years) and 27 HFREF 
patients (mean age = 65±3 years), we found that SDI could diagnose HFREF with an 
AUC of 0.99 (95% CI, 0.98–1.00). In another age-matched subgroup analysis 
regarding systolic dysfunction involving 26 heart failure patients with moderate 
systolic dysfunction (mean age = 70±7 years) and 36 with severe systolic 
dysfunction (mean age = 73±6 years), SDI detected severe systolic dysfunction with 
an AUC of 0.81 (95% CI, 0.71–0.92). Similarly, in one age-matched subgroup 
analysis regarding diastolic dysfunction involving 27 heart failure patients with 
non-severe diastolic dysfunction (mean age = 73±5 years) and 28 with severe 
diastolic dysfunction (mean age = 70±7 years), S3 score discriminated those with 
severe diastolic dysfunction with an AUC of 0.78 (95% CI, 0.65–0.90). Secondly, 
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heart failure cohort in our study was selected from in-patients. Although most of 
them were clinically stable when enrolled, their results may not be applicable to all 
chronic heart failure patients. Thirdly, heart failure patients with AF were not 
excluded from our study. In order to reduce the effect of irregular heart rate, more 
examinations were performed and the average values were used for analysis. Dillier 
R et al also demonstrated that acoustic cardiography could be used for diagnosis of 
LV dysfunction in patients with AF (Dillier et al., 2010). Lastly, there are also other 
factors independent of LV function that can affect acoustic cardiographic variables, 





Chapter 5 Prognostic value of Acoustic Cardiography in Risk Stratification of 
Patients With Heart Failure  
Introduction 
Heart failure is a significant cause of morbidity, mortality, and health care 
expenditures. Patients with heart failure are at high risk for mortality, and there are a 
larger number of variables and models that are predictive of prognosis in these 
patients. (Harjai et al., 2001; Stevens et al., 2003; Felker et al., 2004; Fonarow et al., 
2005; Diercks et al., 2006) However, even with the development of the current 
diagnostic and prognostic tools, the rapid risk stratification in patients with heart 
failure remains poorly defined. Risk stratification is helpful in triaging patients and 
guiding medical decision making, especially for the emergency department 
physicians. 
 
In the previous studies reported in this thesis we have demonstrated acoustic 
cardiography facilitates identification of heart failure and its phenotypes (Wang et al., 
2012) as well as evaluation of the severity of left ventricular (LV) systolic and 
diastolic dysfunction.  
 
The present study was designed to ascertain whether acoustic cardiography could 





The clinical diagnosis of heart failure was based on the Framingham criteria. (McKee 
et al., 1971) Exclusion criteria for heart failure cohort included age < 18 years old, 
systolic blood pressure < 90 mmHg, severe mitral stenosis, constrictive pericarditis, 
use of mechanical ventilation and pacemaker implantation. A total of 507 patients 
with heart failure were consecutively enrolled into our study from August 2008 to 
December 2011, and 33 patients were excluded from analysis due to the poor quality 
of acoustic cardiographic data. There were 474 participants included in our dataset. 
Informed consent was obtained from each patient and the study was approved by 
local ethics committee of the institution. 
 
Acoustic cardiography 
In brief, please refer to methods section in chapter 3. 
 
Echocardiography 
A complete 2-dimensional and Doppler echocardiographic examination was 
performed (Vivid 7, Vingmed-General Electric, Horten, Norway, and IE33, Phillips, 
Andover, MA) in 232 participants. Investigators who interpreted echocardiographic 
findings were blinded to the clinical and acoustic cardiographic data. LV 
end-diastolic (LVEDV) and LV end-systolic volumes (LVESV) were measured and 
LVEF was calculated using the biplane Simpson's method. Early diastolic mitral 
annular velocity (e′) was obtained by pulsed wave Tissue Doppler imaging. 
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Trans-mitral flow velocities were measured by placing a 2mm size sample volume of 
pulsed wave Doppler at the tip of mitral valve leaflets from the apical 4-chamber 
view. Peak early diastolic velocity (E), peak atrial filling velocity (A), E/A ratio, E 
wave deceleration time (DT) and isovolumic relaxation time (IVRT) were measured 




The primary outcome of the present study was all-cause mortality and the secondary 
outcome was cardiac death. 
 
Assessment of reproducibility  
In brief, please refer to methods section in chapter 3. 
 
Statistical analysis 
Data were expressed as mean ± standard deviation for continuous variables and 
frequency (proportion) for categorical variables. Comparisons between groups were 
tested by student's t test for normally distributed data and Mann-Whitney U test for 
skewed data. The cumulative survival curves were plotted via Kaplan-Meier method 
with statistical significance examined by the log-rank test. Cox regression analysis 
was used to identify the predictors for all-cause mortality or cardiac death. Candidate 
variables considered for the final multivariate model were those which were 
previously associated with outcomes in univariate analysis. In subgroup analysis in 
 96 
patients undergoing echocardiography, several echocardiographic parameters were 
also evaluated. A two-sided p value less than 0.05 was considered to indicate 
statistical difference in all analyses. Statistical analyses were performed using SPSS, 




The study population consisted of 474 patients with heart failure. During a mean 
follow-up period of 484±316 days, 169 (35.7%) patients died and 126 (26.6%) of 
them died of cardiac causes. 15 patients died from cancer, 9 from renal failure, 7 
from respiratory failure, 1 from stroke and 11 from undetermined causes. Baseline 
characteristics and acoustic cardiographic results of participants and comparison 
between survivors and non-survivors are listed in Table 5.1 and Table 5.2. 
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Demographics     
Age, year 76±11 76±12 78±11 0.026
Male, n (%) 237 (50) 145 (47.5) 92 (54.4) 0.15 
Vital signs     
Heart rate, bpm 78±16 78±16 79±17 0.564
SBP, mmHg 150±30 152±29 145±31 0.012
DBP, mmHg 78±38 79±19 76±59 0.486
Medical history     
NYHA class, unitless 3.06±0.87 3.01±0.9 3.13±0.83 0.281
Hypertension, n (%) 314 (66.2) 202 (66.2) 112 (66.2) 0.961
Diabetes mellitus, n (%) 196 (41.4) 115 (37.7) 81 (47.9) 0.025
IHD, n (%) 143 (30.2) 89 (29.1) 54 (31.9) 0.531
AF, n (%) 142 (30) 90 (29.5) 52 (30.8) 0.777
CVD, n (%) 60 (12.7) 34 (11.1) 26 (15.4) 0.185
COPD/Asthma, n (%) 39 (8.2) 19 (6.2) 20 (11.8) 0.055
Laboratory findings     
Sodium, mmol/L 139±5 139±5 139±4 0.493
Potassium, mmol/L 4.1±0.6 4.1±0.6 4.1±0.6 0.795
Hemoglobin, g/dL 11.7±2.2 12±2.1 11.2±2.3 <0.001
BUN, mmol/L 11.3±11.5 9.5±5.7 14.6±17.1 <0.001










Albumin, g/L 139±5 37±5 34±5 <0.001
Medications     
Diuretics, n (%) 282 (59.5) 181 (59.3) 101 (59.8) 0.869
ACEIs, n (%) 225 (47.5) 160 (52.5) 65 (38.5) 0.004
ARBs, n (%) 37 (7.8) 26 (8.5) 11 (6.5) 0.444
CCBs, n (%) 133 (28.1) 87 (28.5) 46 (27.2) 0.791
BBs, n (%) 225 (47.5) 156 (51.1) 69 (40.8) 0.036
AA, n (%) 26 (5.5) 16 (5.2) 10 (5.9) 0.747
Digoxin, n (%) 60 (12.7) 38 (12.5) 22 (13) 0.842
Statins, n (%) 116 (24.5) 68 (22.2) 48 (28.4) 0.662
Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; 
NYHA = New York Heart Association; IHD = ischemic heart disease; AF: atrial 
fibrillation; CVD = cerebrovascular diseases; COPD = chronic obstructive 
pulmonary disease; BUN = blood urea nitrogen; ACEI = angiotensin converting 
enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = calcium channel 
blocker; BB = beta blocker; AA = aldosterone antagonist. 
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Table 5. 2 Acoustic cardiographic results of participants and comparison between 
survivors and non-survivors 







QR interval, ms 40±10 41±11 40±8 0.349 
QRS interval, ms 106±28 103±26 109±30 0.029 
QTc interval, ms 414±41 413±41 415±41 0.676 
%EMAT, % 13±4 12.79±3.46 13.41±3.83 0.074 
%LVST, % 39±5 38.87±5.38 39.16±5.67 0.577 
%LDPT, % 48±8 48.5±7.34 47.22±8.24 0.084 
S3 score, unitless 3.87±1.87 3.74±1.88 4.1±1.82 0.046 
SDI, unitless 4.22±2.06 3.98±1.99 4.66±2.11 0.001 
Abbreviations: %EMAT = electromechanical activation time normalized by heart 
rate; %LVST = left ventricular systolic time normalized by heart rate; %LDPT = left 
ventricular diastolic perfusion time normalized by heart rate; S3 = the third heart 
sound; SDI = systolic dysfunction index. 
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All-cause mortality 
Univariate analysis identified age, systolic blood pressure (SBP), hemoglobin (Hb), 
blood urea nitrogen (BUN), albumin, use of angiotensin converting enzyme inhibitor 
(ACEI) or beta blocker, S3 score ≥ 4.12, QRS interval, %EMAT and SDI ≥ 5 as 
significant correlates of all-cause mortality. Because SDI is derived from S3 score, 
QR interval, QRS interval and S3 score, SDI ≥ 5 and the other 3 variables were put 
into separate model in multivariate analysis (Table 5.3). We found that SDI ≥ 5 and 
S3 score ≥ 4.12 were both independent predictors of all-cause mortality after 
adjusting other potential confounders. Kaplan-Meier analysis showed that patients 
with SDI ≥ 5 suffered a significantly lower survival rate than those with lower SDI 
(52.2% vs. 69.2%, log-rank χ2 = 18.07, P < 0.001). (Figure 5.1a) Similar results were 
observed in comparison of survival in patients with S3 score ≥ 4.12 and those with 
lower S3 score (56.3% vs. 68.5%, log-rank χ2 = 11.39, P = 0.001). (Figure 5.1b)  
 
Cardiac death 
In univariate analysis, SBP, diastolic blood pressure (DBP), history of atrial 
fibrillation (AF), BUN, albumin, use of beta blocker or aldosterone antagonist, S3 
score ≥ 4.12, QRS interval, %EMAT and SDI ≥ 5 were found to be the variables 
predictive of cardiac death. In multivariate analysis, SDI ≥ 5 and S3 score ≥ 4.12 
were also identified as most powerful predictors for cardiac death (Table 5.4). In 
Kaplan-Meier analysis, SDI ≥ 5 and S3 score ≥ 4.12 were associated with cardiac 
death (SDI, log-rank χ2 = 42.03, P < 0.001; S3 score, log-rank χ2 = 21.29, P < 0.001). 
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Table 5. 3 Cox proportional hazards model for all-cause mortality in all patients 
(including clinical, laboratory and acoustic cardiographic variables) 
Univariate analysis Multivariate analysis 
Variable 
HR (95% CI) P value HR (95% CI) P value
Model 1     
Age 1.018 (1.003–1.033) 0.015 1.03 (1.014–1.046) <0.001
SBP 0.992 (0.987–0.997) 0.003 0.993 (0.988–0.999) 0.019 
Hb 0.877 (0.817–0.94) <0.001  NS 
BUN 1.032 (1.024–1.041) <0.001 1.029 (1.019–1.039) <0.001
Albumin 0.926 (0.9–0.954) <0.001 0.945 (0.914–0.978) 0.001 
ACEI 0.668 (0.489–0.911) 0.011  NS 
BB 0.672 (0.494–0.915) 0.012  NS 
SDI ≥ 5 1.942 (1.422–2.652) <0.001 2.214 (1.555–3.15) <0.001
Model 2     
Age 1.018 (1.003–1.033) 0.015 1.025 (1.01–1.041) 0.001 
SBP 0.992 (0.987–0.997) 0.003  NS 
Hb 0.877 (0.817–0.94) <0.001  NS 
BUN 1.032 (1.024–1.041) <0.001 1.029 (1.019–1.04) <0.001
Albumin 0.926 (0.9–0.954) <0.001 0.942 (0.91–0.975) 0.001 
ACEI 0.668 (0.489–0.911) 0.011  NS 
BB 0.672 (0.494–0.915) 0.012  NS 
S3 Score ≥ 4.12 1.686 (1.24–2.292) 0.001 1.599 (1.132–2.258) 0.008 
QRS interval 1.009 (1.003–1.014) 0.001 1.006 (1.001–1.012) 0.026 
%EMAT 1.046 (1.004–1.09) 0.031  NS 
Abbreviations: SBP = systolic blood pressure; Hb = hemoglobin; BUN = blood urea 
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nitrogen; ACEI = angiotensin converting enzyme inhibitor; BB = beta blocker; SDI = 








Figure 5. 1 Kaplan-Meier analysis shows patients with SDI ≥ 5 (A) or S3 score ≥ 
4.12 (B) suffered a significantly lower survival rate than those with lower SDI or S3 
score. 
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Table 5. 4 Cox proportional hazards model for cardiac death in all patients (including 
clinical, laboratory and acoustic cardiographic variables) 
Univariate analysis Multivariate analysis 
Variable 
HR (95% CI) P value HR (95% CI) P value
Model 3     
SBP 0.981 (0.971–0.991) <0.001  NS 
DBP 0.973 (0.957–0.99) 0.002 0.971 (0.949–0.994) 0.013 
AF 1.912 (1.112–3.289) 0.019  NS 
BUN 1.028 (1.008–1.049) 0.007  NS 
Albumin 0.906 (0.865–0.949) <0.001 0.919 (0.872–0.969) 0.002 
BB 0.355 (0.199–0.633) <0.001 0.395 (0.209–0.748) 0.004 
AA 2.59 (1.167–5.748) 0.019  NS 
SDI ≥ 5 4.193 (2.433–7.227) <0.001 3.873 (1.974–7.598) <0.001
Model 4     
SBP 0.981 (0.971–0.991) <0.001  NS 
DBP 0.973 (0.957–0.99) 0.002 0.973 (0.95–0.997) 0.028 
AF 1.912 (1.112–3.289) 0.019  NS 
BUN 1.028 (1.008–1.049) 0.007  NS 
Albumin 0.906 (0.865–0.949) <0.001 0.919 (0.871–0.971) 0.002 
BB 0.355 (0.199–0.633) <0.001 0.399 (0.209–0.764) 0.006 
AA 2.59 (1.167–5.748) 0.019  NS 
S3 Score ≥ 4.12 3.309 (1.916–5.715) 0.000 2.29 (1.193–4.394) 0.013 
QRS interval 1.017 (1.008–1.025) <0.001 1.011 (1–1.022) 0.047 
%EMAT 1.118 (1.048–1.191) 0.001  NS 
SBP = systolic blood pressure; DBP: diastolic blood pressure; AF: atrial fibrillation; 
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BUN = blood urea nitrogen; BB = beta blocker; AA: aldosterone antagonist; SDI = 
systolic dysfunction index; EMAT = electromechanical activation time. 
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Subgroup analysis in 232 patients undergoing echocardiography 
There were no significant differences in age, gender, vital signs and major acoustic 
cardiographic variables between patients with and without echocardiographic data 
(Table 5.5). In this cohort, 76 patients died and 55 patients died from cardiac death, 6 
from cancer, 3 from renal failure, 3 from respiratory failure, 1 from stroke and 8 from 
undetermined causes.  
 
In Cox regression analysis of all-cause mortality, only albumin showed independent 
association with outcome in final multivariate model (Table 5.6). Whereas in Cox 
regression analysis of cardiac death, SDI ≥ 5 and S3 score ≥ 4.12 were both 
independent predictors after adjustment for other predictors including 
echocardiographic variables (Table 5.7). 
 
Inter-operator reproducibility 
ICCs for SDI and S3 score were 0.87 (95% CI, 0.71–0.95) and 0.77 (95% CI, 
0.50–0.90), respectively.  
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Table 5. 5 Comparison between patients with and without echocardiographic data 





Age, year 77±12 76±11 0.086 
Gender, n(%) 117 (48%) 120 (51%) 0.462 
Heart rate, bpm 78±15 79±17 0.453 
Systolic blood pressure, mmHg 151±30 148±30 0.214 
Diastolic blood pressure, mmHg 79±50 76±19 0.332 
QR, ms 40±10 41±11 0.347 
QRS, ms 105±27 106±29 0.603 
QTc, ms 412±42 415±40 0.339 
%EMAT, % 12.84±3.55 13.19±3.67 0.298 
%LVST, % 39.15±5.36 38.78±5.61 0.465 
%LDPT, % 48.11±7.43 47.98±7.95 0.861 
S3 score, unitless 3.8±1.74 3.94±1.99 0.394 
SDI, unitless 4.1±1.86 4.35±2.24 0.185 
LVEF, % NA 50±15 NA 
E velocity, m/s NA 0.94±0.4 NA 
A velocity, m/s NA 0.84±0.33 NA 
E/A ratio NA 1.23±1.06 NA 
EDT, ms NA 201±78 NA 
IVRT, ms NA 86±26 NA 
Septal e′ cm/s NA 4.71±1.9 NA 
E/e′ ratio NA 21.05±9.39 NA 
Abbreviations: LVEF = left ventricular ejection fraction; E = early diastolic mitral 
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inflow velocity; A = late diastolic mitral inflow velocity; EDT = deceleration time of 
mitral E velocity; IVRT = isovolumic relaxation time; e′ = early diastolic mitral 
annular velocity. 
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Table 5. 6 Cox proportional hazards model for all-cause mortality in patients 
undergoing echocardiography (including clinical, laboratory, acoustic cardiographic 
and echocardiographic variables) 
Univariate analysis Multivariate analysis 
Variable 
HR (95% CI) P value HR (95% CI) P value
Model 5     
SBP 0.985 (0.977–0.994) 0.001  NS 
BUN 1.026 (1.008–1.045) 0.004  NS 
Albumin 0.905 (0.87–0.941) <0.001 0.893 (0.848–0.94) <0.001
AA 2.112 (1.011–4.41) 0.047  NS 
BB 0.467 (0.291–0.748) 0.002  NS 
EDT 0.995 (0.992–0.999) 0.013  NS 
E/e′ 1.027 (1.004–1.05) 0.021  NS 
LVEF 0.982 (0.968–0.996) 0.014  NS 
SDI ≥ 5 2.261 (1.433–3.57) <0.001  NS 
Model 6     
SBP 0.985 (0.977–0.994) 0.001  NS 
BUN 1.026 (1.008–1.045) 0.004  NS 
Albumin 0.905 (0.87–0.941) <0.001 0.885 (0.839–0.933) <0.001
AA 2.112 (1.011–4.41) 0.047  NS 
BB 0.467 (0.291–0.748) 0.002  NS 
EDT 0.995 (0.992–0.999) 0.013  NS 
E/e′ 1.027 (1.004–1.05) 0.021  NS 
LVEF 0.982 (0.968–0.996) 0.014  NS 
S3 Score ≥ 4.12 2.029 (1.291–3.188) 0.002  NS 
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QRS interval 1.011 (1.004–1.019) 0.003  NS 
%EMAT 1.074 (1.013–1.138) 0.017  NS 
Abbreviations: SBP = systolic blood pressure; BUN = blood urea nitrogen; BB = 
beta blocker; AA: aldosterone antagonist; EDT = deceleration time of mitral E 
velocity; E = early diastolic mitral inflow velocity; e′ = early diastolic mitral annular 
velocity; LVEF = left ventricular ejection fraction; SDI = systolic dysfunction index; 
EMAT = electromechanical activation time 
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Table 5. 7 Cox proportional hazards model for cardiac death in patients undergoing 
echocardiography (including clinical, laboratory, acoustic cardiographic and 
echocardiographic variables) 
Univariate analysis Multivariate analysis 
Variable 
HR (95% CI) P value HR (95% CI) P value
Model 7     
SBP 0.981 (0.971–0.991) <0.001  NS 
BUN 1.028 (1.008–1.049) 0.007  NS 
Albumin 0.906 (0.865–0.949) <0.001 0.898 (0.841–0.959) 0.001 
AA 2.59 (1.167–5.748) 0.019  NS 
BB 0.355 (0.199–0.633) <0.001  NS 
E/e′ 1.037 (1.011–1.063) 0.005  NS 
LVEF 0.974 (0.958–0.991) 0.002  NS 
SDI ≥ 5 4.193 (2.433–7.227) <0.001 4.333 (1.644–11.42) 0.003 
Model 8     
SBP 0.981 (0.971–0.991) <0.001  NS 
BUN 1.028 (1.008–1.049) 0.007  NS 
Albumin 0.906 (0.865–0.949) <0.001 0.885 (0.828–0.947) <0.001
AA 2.59 (1.167–5.748) 0.019  NS 
BB 0.355 (0.199–0.633) <0.001 0.402 (0.17–0.949) 0.038 
E/e′ 1.037 (1.011–1.063) 0.005  NS 
LVEF 0.974 (0.958–0.991) 0.002  NS 
S3 Score ≥ 4.12 3.309 (1.916–5.715) <0.001 3.604 (1.516–8.566) 0.004 
QRS interval 1.017 (1.008–1.025) <0.001  NS 
%EMAT 1.118 (1.048–1.191) 0.001  NS 
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Abbreviations: SBP = systolic blood pressure; BUN = blood urea nitrogen; BB = 
beta blocker; AA: aldosterone antagonist; E = early diastolic mitral inflow velocity; 
e′ = early diastolic mitral annular velocity; LVEF = left ventricular ejection fraction; 
SDI = systolic dysfunction index; EMAT = electromechanical activation time. 
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Discussion 
Our results demonstrated that SDI and S3 score obtained by acoustic cardiography 
were both strong independent predictors of mortality in patients with heart failure. 
SDI ≥ 5 and S3 score ≥ 4.12 were associated with a significant increased risk for 
all-cause mortality and cardiac death. 
 
Two previous studies had assessed prognostic value of S3 score and %EMAT 
obtained by acoustic cardiography. Collins et al. (Collins et al., 2009) found that S3 
detected by acoustic cardiographic (defined as S3 score ≥ 5) added no prognostic 
information on 30-day or 90-day events. One possible explanation for this result is 
that the authors of this study used different cut-off value of S3 score from ours .Chao 
et al. conducted one study involving 45 patients with acute heart failure and 
identified %EMAT ≥ 15 is useful in the prediction of cardiovascular events 
independent of LVEF, E/e′, and BNP. However, the conclusion of this study is 
limited by its small sample size.  
 
Rapid risk stratification in patients with heart failure is critically important for a 
better therapy optimization and outcome improving but remains poorly defined and 
challenging. S3 has been demonstrated as one marker for adverse outcome of 
patients with heart failure. (Drazner et al., 2001; Drazner et al., 2003) however, its 
clinical applications were limited by the poor inter-observer agreement in 
auscultation. The STIs were the first quantitative non-invasive method to evaluate 
LV dysfunction. Whereas their clinical value diminished due to the complicated 
measurement that involved ECG, phonocardiography and carotid pulse tracing 
especially after the advent of echocardiography. 
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A comprehensive echocardiographic examination indeed can diagnose and provide 
prognostic insights for heart failure. However, echocardiography requires high skills 
in image acquisition and interpretation as well time consuming when compared with 
acoustic cardiography. Further, echocardiography can be prohibitive as an initial test 
in emergent department due to lack of immediate availability and high cost. Acoustic 
cardiography cannot substitute to the traditional modalities in management of heart 
failure but could be used in adjunction for more rapid evaluation and assessment.  
 
Strengths and potential limitations 
Our study is prospectively designed with a prespecified hypothesis instead of 
retrospective review of clinical variables like some studies. The moderate sample 
size and the high level of statistical significance observed for target parameters 
confirm the clinical relevance of our conclusions. To our knowledge, the present 
study is the largest one exploring the prognostic value of acoustic cardiographic 
STIs. 
 
Several limitations also need to be considered. Firstly, adverse non-fatal outcomes 
like rehospitalization or severe medical complications were not evaluated in this 
study. Further investigations focusing on the subsequent cardiovascular events are 
warranted. Secondly, because heart failure patients did not undergo BNP test 
routinely in Hong Kong and it is unavailable to most subjects in our dataset, we did 
not include this biomarker in the analysis. Thirdly, heart failure patients with atrial 
fibrillation were not excluded from our study. In order to reduce the effect of 
irregular heart rate, more examinations were performed and the average values were 
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used for analysis. Dillier R et al (Dillier et al., 2010) also demonstrated that acoustic 
cardiography could be used for diagnosis of LV dysfunction in patients with atrial 
fibrillation. Fifthly, Heart failure cohort in our study was selected from patients 
hospitalized for heart failure. Although most of them were clinically stable when 
enrolled, their results may not be applicable to all chronic heart failure patients. 
Lastly, there are also other factors independent of LV function that can affect acoustic 
cardiographic variables, such as the presence of left bundle branch block, mitral 












PART III CONCLUSIONS 
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Chapter 6 Summary of the Present Studies 
The studies in the present thesis addressed 3 major issues in the clinical application 
of acoustic cardiography: identification of heart failure and its phenotypes; 
assessment of HFREF patients at high risk by evaluating the severity of LV systolic 
and diastolic dysfunction; utility of risk stratification in patients with heart failure. 
 
I. Identification of heart failure and its phenotypes 
Study 1: Acoustic Cardiography Helps to Identify Heart Failure and Its Phenotypes 
 
In this study, we sought to determine whether this new technology could accurately 
identify heart failure and its phenotypes. Ninety-four patients with hypertension 
without heart failure, 109 patients with HFNEF (EF > 50%) and 89 patients with 
HFREF (EF < 50%) were consecutively enrolled into our study. We observed that 
%EMAT significantly differentiated HFNEF from hypertension (AUC, 0.83; 95% CI, 
0.77–0.89) with a %EMAT > 11.54% yielded 55% sensitivity and 90% specificity. 
Similarly, an echo-measured E/e′ > 15 yielded 55% sensitivity, 90% specificity and 
0.84 AUC in detecting HFNEF. Whereas SDI out-performed the other acoustic 
cardiographic parameters in differentiating HFREF from HFNEF (AUC, 0.81; 95% 
CI, 0.75- 0.87), an SDI > 5.43 yielded 53% sensitivity and 91% specificity. The E/e′ 
ratio had a similar diagnostic performance. 
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II. Assessment of HFREF patients at high risk by evaluating the severity of LV 
systolic and diastolic dysfunction 
Study 2: Rapid Bedside Identification of High-Risk Population in Heart Failure with 
Reduced Ejection Fraction by Acoustic Cardiography 
 
In this study, we sought to investigate whether acoustic cardiography can identify 
these high-risk patient subgroups in HFREF. Ninety-four hypertensive patients 
without heart failure and 127 HFREF patients (EF < 50%) were consecutively 
recruited for the study. SDI significantly differentiated HFREF from hypertension 
(AUC, 0.97; 95% CI, 0.95–0.99) with an SDI > 3.27 that yielded 93% sensitivity and 
91% specificity. In subgroup analysis, SDI discriminated (AUC, 0.79; 95% CI, 
0.71–0.87) HFREF patients with severely impaired EF (EF ≤ 35%) from those with 
moderately impaired EF (35% < EF <50%) with an SDI > 5.16 that yielded 85% 
sensitivity and 64% specificity. An S3 score > 4.67 identified HFREF patients with 
restrictive LV filling pattern with 0.76 AUC (95% CI, 0.67–0.84), 70% sensitivity 
and 73% specificity. 
 
III. Risk stratification in patients with heart failure 
Study 3: Prognostic value of Acoustic Cardiography in Risk Stratification of Patients 
With Heart Failure 
 
The aim of this study is to ascertain whether acoustic cardiography can identify heart 
failure patients at high risk for mortality. A total of 474 patients hospitalized for heart 
failure were enrolled into our study. During a mean follow-up time of 484±316 days, 
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169 (35.7%) patients died and 125 (26.4%) of them died of cardiac causes. After 
controlling for age, SBP, hemoglobin, BUN, as well as ACEI and beta-blocker 
administration in multivariate Cox regression analysis, we found that S3 score ≥ 4.12, 
SDI ≥ 5 were both the most powerful predictors for all-cause mortality. 
Kaplan-Meier analysis showed that heart failure patients with SDI ≥ 5 or S3 score ≥ 
4.12 had a significantly lower survival rate (52.2% vs. 69.2%, log Rank χ2 = 18.07, P 
< 0.001; 56.3% vs. 68.5%, log-rank χ2 = 11.39, P = 0.001) than those with lower SDI 
or S3 score. 
 
The conclusions of the studies reported herein can be summarized as follows: 
Acoustic cardiography could (1) facilitate identification of heart failure and its 
phenotypes; (2) identify HFREF patients at high risk by evaluation of the severity of 
LV systolic and diastolic dysfunction; (3) provide important prognostic information 
in heart failure patients and identify those at high risk for mortality.  
 
Acoustic cardiography will potentially improve diagnosis, assessment and initial 
disposition decisions in management of heart failure patients, acting as an early 
detection, evaluation and risk-stratification tool. 
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Chapter 7 Future Research Directions 
Extensive studies demonstrated the utility of acoustic cardiography in diagnosis of 
heart failure or LV dysfunction (Marcus et al., 2005; Collins et al., 2006; Moyers et 
al., 2007; Shapiro et al., 2007; Zuber et al., 2007; Roos et al., 2008; Collins et al., 
2009; Kosmicki et al., 2010), detection of ischemia (Lee et al., 2009; Lee et al., 2009; 
Lee et al., 2009), assisting physicians in auscultation (Marcus et al., 2006; Gupta and 
Michaels, 2009; Michaels et al., 2010) and optimization in CRT (Hasan et al., 2006; 
Toggweiler et al., 2007; Zuber et al., 2008; Taha et al., 2010). However, the 
following aspects have not been fully explored.  
 
Due to its inexpensive, noninvasive and easy-to-use characteristics, acoustic 
cardiography has an obvious advantage that multiple observations can be performed. 
This allows an opportunity to assess changes of clinical status in heart failure patients 
and their response to therapeutic interventions, which will facilitate timely 
recognition and treatment of those at significant risk for morbidity and mortality.  
 
Another specific example of the value in detecting changes in hemodynamic status is 
following patients receiving cardiotoxic agents such as doxorubicin and other 
anthracycline derivatives, which currently involves repetitive echocardiographic 
exam. Owing to the high cost and need for skilled technicians, in the absence of 
some other clinical indications, routine comprehensive echocardiography cannot be 
performed frequently. 
 
It is now well established that half of the heart failure patients are HFNEF (Paulus et 
al., 2007), whereas the rapid and accurate diagnosis of HFNEF is difficult. The 
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primary symptom of HFNEF patients is breathlessness on exercise due to the more 
apparent LV dysfunction on exercise. The diagnostic and prognostic value of acoustic 
cardiographic examination on exercise is unknown.  
 
In conclusion, acoustic cardiography is a rapid and non-invasive cardiac examination 
which can be used in a variety of clinical settings. The further studies may focus on 
the continuous monitoring of hemodynamic status and the diagnostic and prognostic 
value of acoustic cardiography on exercise. 
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